Also available in Sri Lanka, Malaysia, Singapore, Thailand, Taiwan, China & Hong Kong
Editorial
Change: The constant companion
D
o we desire a world where one would still be totally relying on nature for getting cured? Ingesting a bark or a herb to take care of our gastric problems! Or, when we suffer from headache, there is no remedy apart from sleep or applying some thick malodorous paste!
In contrast, the pharmaceutical world of today offers a variety of medicines in a wide array of delivery modes to meet the needs of the consumer. All these are but examples of the multi-faceted changes that the pharma sector has witnessed in the recent years. Further, the ways in which these changes and trends in healthcare will impact providers and consumers are still evolving and open to challenging opportunities. Change is not something new for an organisation of any size or industry. In fact, the progressive ones make that significant difference by managing change in a sustainable manner. Some of the real-life scenarios include implementing new hardware and software, mergers and acquisitions, relocation of facilities, adopting processes to do more with less resource, etc. On a more sophisticated level, it can involve implementation of a strategic planning process, a specific quality management programme, process re-engineering, among others. A few months ago, we had embarked on a similar journey to ‘challenge and change’ ourselves, more precisely, our brands, for better. In this exciting and challenging sojourn, we revisited & thoroughly analysed every practical aspect of our motto of providing information empowerment to you - our audience - and not merely publishing content. Although we have put our best efforts towards perfecting the products and practices further, we would also submit that the best practices for managing change are still elusive.
Editorial Advisory Board Ajit Singh Chairman, ACG Worldwide & Head, ISPE
Dr Abraham Patani Past President, IDMA & CMD, Inga Laboratories
Dr Gopakumar G Nair
The result is there for you to see in this new avatar of Modern Pharmaceuticals. From the brand new sections to focussed features, emphasis has been laid on ensuring more analytical, in-depth and contemporary first-hand information. Of course, all these are presented in a lucid and elegant way, thanks to an optimum combination of applying mind over matter as well as some of the latest publishing software. Rather than blowing our own trumpet, we will prefer your valuable feedback on these initiatives. Suffice to say, it will help us in our constant endeavour to help you in terms of receiving superior value on a sustained basis. Let there be more information empowerment towards better decision making. Here’s to our constant companion – change!
IPR Consultant & Advisor
Dilip G Shah Chairman, IGPA & Secretary General, IPA
Daara Patel Secretary General, IDMA
Manas R Bastia manas@infomedia18.in
November 2011 I Modern Pharmaceuticals
9
Contents
24
REGULAR SECTIONS
In Conversation With Dr T S Balganesh Vice President, iScience Bangalore, AstraZeneca India Pvt Ltd
Special Focus
Pharma machinery .......................... 27
9 14 20 22 72 74 79 80 90 91
Editorial News, Views & Analysis Technology & Innovation Technology Transfer Projects Event List Book Review Products List of Products List of Advertisers
Automation Trends Single-use pharma technology ........................................ 28 Advances in tablet coating machine ................................. 32
Pharma manufacturing Automation, the need of the hour ..............................56
Interface - Rajesh Shah .................................................. 36
Didier Lacroix, Senior Vice President - Worldwide Sales & Marketing, Cognex Inc
Roundtable .................................................................... 37
Energy Management 38 Facility Visit Kewaunee Scientific Corporation Leaders of technical guidance and labs in India
Insight & Outlook
Pharma raw materials ........... 41
Green engineering Reducing carbon footprint in pharma manufacturing ...............................................58 Dr A Rajakumar, Department of Chemistry, IIT Kharagpur
Policies & Regulations FDI in Indian pharma Evaluating the pros & cons ........................................62
Strategy Marketing of drugs The importance of listening .......................................68 Dr Rajan T D, Pharma Consultant & Practising Dermatologist
High potency APIs market in India ................................. 42 Indian market for penicillin ............................................ 46 Interface - K V Ranga Rao .............................................. 52 Roundtable .................................................................... 54
Tips & Tricks Refurbished pharma machinery Things to look out for while buying ...........................70 Matthew W Smith, Vice President – Corporate Marketing, EquipNet, Inc, USA
Event Preview Highlights of Next Edition Special Focus: Pharma education & policies Insight & Outlook: Pharma packaging
Details on page no. 40, 47, 48
Note: ` stands for Indian rupee, $ stands for US dollar and £ stands for UK pound, unless mentioned otherwise
November 2011 I Modern Pharmaceuticals
PMEC & CPhI India 2011 A congregation of the who’s who of the industry ....... 77 Indian Pharmaceutical Congress 2011 Showcasing India as the global pharma power house ........................................ 78
11
FOUNDER & EDITOR, NETWORK 18 Raghav Bahl
GROUP CEO, NETWORK 18 Haresh Chawla
PRESIDENT & EDITORIAL DIRECTOR, TV 18 Senthil Chengalvarayan
GROUP COO, NETWORK 18 B Sai Kumar
SENIOR EDITOR Manas R Bastia FEATURES EDITOR Arshia Khan EDITORIAL TEAM Chandreyee Bhaumik, Parita Dholakia, Michael Anthony, Abha Mishra, Paskaline Sebastian, Titash Roy Choudhury (Delhi), Jasleen Kaur Batra (Bengaluru) ASSISTANT ART DIRECTOR Varuna Naik DESIGN Sachin Bhogate CHIEF PHOTOGRAPHER Mexy Xavier PHOTOGRAPHY Neha Mithbawkar, Joshua Navalkar BUSINESS CONTROLLERS Pukha Dhawan, Lovey Fernandes, Akshata Rane, Deepak Bhatia, Shwetha ME, Jayashree N, Sugandha Kulkarni, Shefali Mahant
PRINTING EXECUTIVE VICE PRESIDENT Ananth R Iyer ASSISTANT GENERAL MANAGER - PPC Shekhar Khot
PRODUCTION TEAM Pravin Koyande, Dnyaneshwar Goythale, Vikas Bobhate, Ravikumar Potdar, Ravi Salian, Sanjay Shelar
OVERSEAS CONTACT Ringier Trade Media Ltd
CHINA 1001 Tower 3, Donghai Plaza, 1486 Nanjing Road, West, Shanghai 200040, China Tel: +86-21 6289 – 5533 Ext. 368, Fax: +86-21 6247 – 4855 (Craig Shibinsky) Email: craig@ringier.com.hk Ringier Trade Media Ltd HONG KONG 9/F, Cheong Sun Tower, 118 Wing Lok Street, Sheung Wan, Hong Kong Tel: +852 2369 – 8788 Ext. 21, Fax: +852 2869 – 5919 (Octavia Au-Yeung) Email: octavia@ringier.com.hk Ringier Trade Media Ltd TAIWAN Room 3, Fl. 12, No. 303, Chung Ming S. Rd., Taichung, Taiwan Tel: +886-4 2329 – 7318 Ext. 16, Fax: +886-4 2310 – 7167 (Sydney La) Email: sydneylai@ringier.com.hk
Ringier Trade Media Ltd
GERMANY, AUSTRIA, SWITZERLAND Tel: +41-44 734 0472, Fax: +41 44 734 0680 Email: info@islerannoncen.ch USA Tel: (513) 527-8800 Fax: (513) 527-8801 Email: dhight@gardnerweb.com
USA Alfredo Domador, 6505 Blue Lagoon Drive, Suite 430 Miami, FL. 33126, USA Tel: (305) 448-6875, Fax: (305) 448-9942
CEO-PUBLISHING, INFOMEDIA 18 Sandeep Khosla EVP-HUMAN RESOURCES Sanjeev Kumar Singh ASSOCIATE VICE PRESIDENT Sudhanva Jategaonkar ADVERTISING SALES Shashin Bhagat (Ahmedabad) shashin.bhagat@infomedia18.in Mahadev B (Bengaluru) mahadev.b@infomedia18.in Hari Hara Subramaniam (Chennai) hari.s@infomedia18.in Prakash N (Coimbatore) prakash.n@infomedia18.in Rahul Hanchate (Hyderabad) rahul.hanchate@infomedia18.in Ameya Gokhale (Indore) ameya.gokhale@infomedia18.in Durgesh Grover (Jaipur) durgesh.grover@infomedia18.in Abhik Ghosal (Kolkata) abhik.ghosal@infomedia18.in Inder Dhingra (Ludhiana) inder.dhingra@infomedia18.in Mukesh Yadav (New Delhi) mukesh.yadav@infomedia18.in Rohit Dass (Pune) rohit.dass@infomedia18.in Chirag Pathak (Vadodara) chirag.pathak@infomedia18.in MARKETING TEAM Ganesh Mahale, Prachi Mutha, Varsha Nawathe, Abhay Borkar
NEWSSTAND AND SUBSCRIPTIONS DISTRIBUTION HEAD Sunil Nair DEPUTY GENERAL MANAGER Manoj Palsay SENIOR MANAGER - SUBSCRIPTIONS Sheetal Kotawdekar CO-ORDINATORS Rahul Mankar, Anant Shirke, Sarita Quadros, Chaitali Parkar, Kamlesh Mathkar, Vaibhav Ghavale
SERVICES SUBSCRIPTION SERVICES For subscription queries, write to chaitali.parkar@infomedia18.in or call +91 22 30034631-34 or toll free 1800 200 1021 PERMISSIONS For subscription to copy or reuse material from Modern Pharmaceuticals, Write to spedit@infomedia18.in • Monthly Issue Price: ` 100 • Annual Subscription: ` 799
Views and opinions expressed in this magazine are not necessarily those of Infomedia 18 Ltd, its publisher and/or editors. We at Infomedia 18 Ltd do our best to verify the information published but do not take any responsibility for the absolute accuracy of the information. Infomedia 18 Ltd does not accept the responsibility for any investment or other decision taken by readers on the basis of information provided herein. Infomedia 18 Ltd does not take responsibility for returning unsolicited material sent without due postal stamps for return postage. No part of this magazine can be reproduced without the prior written permission of the publisher. Infomedia 18 Ltd reserves the right to use the information published herein in any manner whatsoever.
Infomedia 18 Ltd is the publishing arm of Network 18.
Printed by Mohan Gajria and published by Lakshmi Narasimhan on behalf of Infomedia 18 Ltd. Senior Editor: Manas R Bastia Printed at Infomedia 18 Ltd, Plot no.3, Sector 7, off Sion-Panvel Road, Nerul, Navi Mumbai 400 706, and published at Infomedia 18 Ltd, ‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W), Mumbai - 400 028. Modern Pharmaceuticals is registered with the Registrar of Newspapers of India under No. MAHENG / 2008 / 27125. Infomedia 18 Ltd does not take any responsibility for loss or damage incurred or suffered by any subscriber of this magazine as a result of his/her accepting any invitation/offer published in this edition.
November 2011 I Modern Pharmaceuticals
13
News,Views & Analysis Lupin receives final FDA approval for generic LoSeasonique® tablets Lupin Pharmaceuticals Inc, a subsidiary of Lupin Ltd, has received US Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA Levonorgestrel and Ethinyl Estradiol tablets 0.1 mg/0.02 mg and Ethinyl Estradiol tablets 0.01 mg. The company has got the approval to market a generic version of Teva Women’s Health,
Inc’s LoSeasonique® tablets. Lupin believes that it is one of the first applicants to file an ANDA for LoSeasonique® tablets and will be entitled to 180 days of marketing exclusivity. Commenting on the launch, Nilesh Gupta, Group President, Lupin, said, “We are happy to receive this approval. This product approval
NATCO signs up with Mabxience for mAbs
NATCO Pharma Ltd, the Hyderabad based company has entered into an exclusive agreement with Mabxience, the bio-similar division of Chemo Sa Lugano, Switzerland for the purchase of four mAb drug substances and use the same for manufacturing finished dosage pharmaceutical formulations. Three of these products, trastuzumab, bevacizumab,
rituximab belong to the oncology segment, while etanercept is for autoimmune diseases. Under the agreement, NATCO will manufacture drug products, undertake local clinical trials, file registration of dossiers, apply for market authorisations and to commercialise the product in India and a few other Asian countries. Oncology is the largest therapy area within the mAb market, with eight marketed products. Worldwide, the market for mAbs has grown rapidly and is currently at a revenue level of around $ 35 billion.
demonstrates our commitment to deliver a quality oral contraceptive pipeline to consumers in the US, built around our development and vertically integrated manufacturing strengths. Consumers can be assured that they are receiving quality products that they have been accustomed to, and at a more affordable price.”
Piramal Healthcare resolves patent litigation with Baxter for inhaled anaesthetic drug Piramal Critical Care, Inc, a subsidiary of Piramal Healthcare Ltd, has announced the dismissal of patent litigation with Baxter Healthcare Corp. The patent litigation over Baxter’s inhaled anesthetic drug Suprane (desflurane) was dismissed by the United States District Court for the District of Delaware pursuant to a settlement between the parties. According to the statement Piramal may launch its generic desflurane product in the United States market by January 1, 2014 but subject to US regulatory approval. Piramal has agreed not to make, use, sell or offer for sale in the United States, or import into the US, this product prior to January 1, 2014. However, the company has taken a licence under the patent pursuant to which the parties have agreed that Piramal may manufacture its generic desflurane in the US as of April 24, 2012 solely for sale outside the US.
Avesthagen Ltd forms JV with SAVA Medica Avesthagen Ltd, a fully integrated life sciences genomic healthcare company, and SAVA Medica Ltd, an emerging fast growing global pharmaceutical company with business verticals across the pharma value chain have formed a 50:50 Joint Venture ( JV) in Avesthagen Ltd’s Dhanvantari Botanicals subsidiary to market and sell a line of Avesthagen Ltd bioactive products in the US and Brazil, Russia, India, and South Africa (BRIS). Dhanvantari Botanical’s products include 11 over-the-counter (OTC) brands (AmlaPure™, Ashwagandha™, BosWell™, Gymnema™, ThinkWell™, Tribulus™, Triphala™, TriplaLax™, WinterWell™,
14
XanoMax™, and GojiMax™) and highly qualified bulk ingredients for the wellness and nutraceutical markets. With this JV agreement, Avesthagen grants and SAVA Medica Ltd earns exclusive marketing rights for Avesthagen’s seven lead first generation scientifically validated and clinically active research products (AvestaDHA™, Smartchol™, Prova™, Teestar™, Cincata™, Bonaphyte™, and Phytossea™). Dr Viloo Morawala-Patell, Founder and CMD, Avesthagen Ltd, said, “This transaction mirrors the clear segregation of the nutrition industry into general wellness, preventive nutraceuticals, and
medical nutrition. This deal falls under general wellness for the 11 OTC products and under preventive nutraceuticals for the 7 bioactive products.” Under the terms of the deal, Avesthagen Ltd will receive upfront payments and a 15 per cent royalty on product net sales in the stated territories. Vinod Jadhav, Founder & Managing Director, SAVA Medica Ltd, said, “Our collective commitment to human healthcare is reflected in this JV that will benefit large populations in the emerging markets by providing access to these excellent preventive healthcare and general wellness products.”
Modern Pharmaceuticals I November 2011
News,Views & Analysis Baxter launches Flexbumin™ Baxter India, a fully-owned subsidiary of Baxter International Inc launched Flexbumin™ [Albumin (Human)] Solution, the first preparation of human albumin to be packaged in a flexible container in India. This US FDA approved Flexbumin™, which is a sterile, non-pyrogenic preparation of albumin in a single dosage form for intravenous administration. Flexbumin uses Baxter’s GALAXY® flexible container system, a proprietary multi-layer system that helps maintain albumin quality and allows the solution to be stored at less than 300°C for up to 2 years. Flexbumin is made from human plasma and products made from human plasma may carry a risk of transmitting infectious agents, such as viruses, that can cause disease. So GALAXY employs barrier technology and a continuous aseptic filling process. It will be available in both 50 ml and 100 ml flexible containers. Flexbumin is indicated in hypovolemia, hypoalbuminemia due to excessive catabolism, haemorrhage, major surgery or burns, and for use during cardiopulmonary bypass surgery.
Glenmark wins two global recognitions by SCRIP Glenmark Pharmaceuticals Ltd, was honoured two global awards by SCRIPS for its business excellence and innovative R&D capabilities. The company has received ‘Best Company in Emerging Markets’ & ‘Best Overall Pipeline’ recognitions for the year 2011 by SCRIP, a global pharmaceutical and biotech news publication at London. “On behalf of our 8,000 employees worldwide, we are honoured to receive two prestigious distinctions from a reputed organisation like Informa Healthcare, which hosts the SCRIP Awards,” said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Ltd. “We are specially delighted at having bagged the ‘Best Overall Pipeline’ distinction, which is a testimony of our world-class R&D capabilities and an enormous tribute to all our research staff around the world who have committed themselves over many years to the development of our innovative pipeline,” he added.
Kaushik Desai appointed as DIA India Director Drug Information Association (DIA) has announced the appointment of Kaushik Desai as Director, DIA India. Desai brings to DIA both a deep knowledge of the global regulatory framework and the pharmaceutical environment in India as well as a passion for the vision and mission of the association. Desai is a trained pharmacist with more than 25 years of experience in key management positions with MNCs and domestic firms. Through 2010, he worked as CEO and Director, Global Pharmatech in Bengaluru. He currently serves as Vice President of the Indian Pharmaceutical Association (IPA) and Chairman of the Industrial Pharmacy Division. Commenting on this appointment, Paul Pomerantz, Executive Director, DIA Worldwide, said, “We are delighted to have someone of Desai’s stature and experience to provide leadership to DIA India.” He continues, “He will work closely with the Advisory Council of India to help address the many opportunities in this country.”
November 2011 I Modern Pharmaceuticals
15
News,Views & Analysis Surya Pharma launches neuropsychiatric division
Surya Pharmaceutical has launched its super specialty neuropsychiatric division called Alvin with 160 sales professionals and will be covering around 15,000 leading neurologists, psychiatrist and neurophysicians. Rajiv Goyal, Chairman & Managing Director, Surya Pharma, said that the size of the neuropsychiatric market in India is around ` 3,000 crore, growing annually at a rate of
15 per cent and the company has forayed into the domain to leverage this potential. In the first phase, Alvin will come up with 15 major neuropsychiatric molecules. In the second phase, the group is planning to launch two formulations for the first time in India (escitalopram + olanzapine & dapoxetine + sildenafil). “The major therapeutic segments being covered under the division are anti-epileptic, anti-depressant, anti-psychotic, anti-migraine, anxiolytic & sexual dysfunction, prokinetic etc,” Goyal added. With the launch of Alvin, the company is targeting a sales of ` 15 crore in the first year, ` 26 crore in the second year and ` 40 crore in the third year, Goyal said.
Matrix completes name change to Mylan Mylan Inc, has announced that its India-based subsidiary, Matrix Laboratories Ltd, has formally changed its name to Mylan Laboratories Ltd with immediate effect. Commenting on this, Robert J Coury, Chairman & CEO, Mylan Inc, said, “With the name change we are excited to operate in India under one powerful brand. For the last 50 years, Mylan name has stood for high quality products, continuous innovation,
serving unmet needs, etc. We look forward to further educating customers, physicians, pharmacists and patients about the Mylan brand as we continue to grow our existing business and launch in the Indian commercial market in the coming months.” The name change has been approved by the Registrar of Companies in India. Mylan intends to retain the Matrix name for its institutional ARV franchise.
Eli Lilly has new chairman for India operations Eli Lilly and Company announced a change in guard at its Indian operations with currently serving Sandeep Gupta announcing his move to pursue another career opportunity after spending over 5 years in the role. The company has got Melt van der Spuy, a citizen of South Africa with varied experience in multiple geographies to succeed as the new Chairman & Managing Director, effective November 1, 2011. Melt had joined Lilly 18 years ago as a sales representative in South Africa. He then held various marketing positions in South Africa and Indianapolis.
16
Modern Pharmaceuticals I November 2011
News,Views & Analysis Stempeutics starts clinical trial with financial support from DBT Stempeutics Research a group company of Manipal Education & Medical Group announced that it has received Department of Biotechnology (DBT) funding under Biotechnology Industry Partnership Program (BIPP) for starting phase II clinical trial of its Investigational Medicinal Product ‘Stempeucel’ in patients with alcoholic liver cirrhosis. Earlier the company received DCGI clearance for starting this trial and subsequently applied for DBT funding. The trial will be funded jointly by Stempeutics & DBT. DBT will be funding up to ` 3.5 crore towards this trial. This is the first time that the DBT has awarded a private organisation for conduct of a stem cell clinical trial. Successful outcome of this clinical trial will have huge impact in India and worldwide.
ACRO welcomes move making registration mandatory for Ethics Committee
The Association of Contract Research Organizations India (ACRO) India has welcomed the decision of the Drugs Technical Advisory Board (DTAB) making it mandatory for all Ethics Committees attached with clinical trial organisations to register with the Drugs Controller General of India (DCGI). The decision by DTAB on technical matters will give a much needed shot in the arm to ACRO India’s efforts of promoting best practices in the clinical research space
in the country. Commenting on the development, Apurva Shah, Chairman, ACRO, said, “This move is in line with our efforts of building a sound regulatory framework that would assist in setting new benchmarks for clinical practices in India. As an industry, CROs in India have been complying fully with both Indian and international standards and some of them have even won accolades for their compliance.” This development comes almost two years after the DCGI first made the registration of clinical trials in India mandatory. Following this decision, henceforth, the DCGI will not provide a sanction for beginning of clinical studies in the country.
‘Stempeucel’ is developed from allogeneic mesenchymal stem cells derived from donated bone marrow using Stempeutics proprietary technology. A total of 60 patients will be recruited across 5 hospitals. All patients will be followed up for 2 years after the injection of Stempeucel. B N Manohar, CEO, Stempeutics Research said, “We would like to thank DBT & DCGI for encouraging the stem cell companies in harnessing the potential of stem cells in the drug development program. We are the only stem cell company in India to have achieved this significant milestones. Our team is working towards launching the first “off-the-shelf ” adult allogeneic stem cell product in the Indian market by the end of 2014.
Lilly Foundation commits $30 million to Lilly MDR-TB Partnership The Eli Lilly and Company Foundation has recently committed $ 30 million in funding to further support The Lilly MDR-TB Partnership in its fight against multidrug- resistant tuberculosis – a disease that disproportionately affects developing countries and kills more than 1,50,000 people each year. Eli Lilly and Company recently launched The Lilly MDR-TB Partnership in 2003 to strengthen the global battle against multidrug-resistant tuberculosis (MDR-TB). Lilly originally committed $70 million to launch the partnership, elevate MDR-TB on the global health agenda and transfer technology for two Lilly medicines used to treat MDR- TB to other manufacturers. In 2007, Lilly expanded the original duration and scope for the partnership by committing an additional $ 50 million to the collaboration – and another $ 15 million for early drug discovery efforts – to complete the technology transfer and to further strengthen awareness, prevention and care for patients who suffer from MDR-TB and TB. The Lilly Foundation has now committed an additional $ 30 million to support a third and final stage of the partnership. This funding will be used to advance the partnership’s efforts in two key areas of focus over the next five years (2012-2016).
Honeywell introduces new ultra-high barrier film for pharma packaging Honeywell recently introduced a new pharma packaging film that provides the highest moisture barrier of any film of its type. Part of the Aclar® family of films, Aclar UltRx 6000, is effective at protecting moisture-sensitive medicines in all climates, even the hottest and most humid locations. This allows pharma companies to standardise their product packaging
with one solution that will work in all regions of the world. “This Aclar film gives pharma companies a clear, ultra-high barrier choice for their most moisture-sensitive drugs sold in the most challenging regions,” said Jeff Czarnecki, global leader of Honeywell’s healthcare and packaging business. “This new film will help pharma companies around the world
protect their medicines, simplify their supply chains, and improve their branding.” Aclar films are based on polychlorotrifluoroethylene (PCTFE) fluoropolymer technology. They can facilitate increased patient compliance with doctor prescriptions with see-through, portable and patientfriendly pack presentations.
Contributed by: Arshia, Chandreyee Bhaumik & Titash Roy Choudhury
18
Modern Pharmaceuticals I November 2011
Technology & Innovation PerkinElmer unveils NexION enhanced security software PerkinElmer, a provider of analytical solutions, has introduced NexION enhanced security (ES) software, to streamline regulatory compliance by pharmaceutical companies. This new software platform will ensure the integrity of electronic data records that are generated under industry standard protocols within pharmaceutical research. The software would combine the power of the Microsoft Windows 7 operating system with that of laboratory networks to provide improved performance for all analytical techniques. NexION ES has been developed for pharma lab instruments to simplify technical compliance with US Food and Drug Administration (USFDA) 21 Code of Federal Regulations (CFR) Part 11 regulations. In addition, the system provides user level management file protection, audit trails and is compatible with all NexION 300 ICP-MS instruments.
Bio-Rad Laboratories, Inc launches PROTEAN i12 IEF Bio-Rad Laboratories, Inc announces the launch of the PROTEAN i12 IEF system the industry’s only IsoElectric Focusing (IEF) system, which is designed to simultaneously run up to 12 immobilised pH gradient (IPG) strips in 12 independently programmed lanes. The PROTEAN i12 IEF system controls lanes separately, allowing researchers to set precise current limits for each lane. Th is enables the system to run different samples and pH ranges simultaneously, while preventing differing samples from affecting each other, resulting in more reliable and reproducible focussing. The system also lets researchers test several optimisation conditions simultaneously and run samples from different experiments together, both of which will speed their time to results. “The system is cost effective as individually powered lanes allow researchers to optimise their sample preparation and first-dimension isoelectric focussing conditions to ensure adequate separation of complex samples in less time than traditional systems,” informed Katy McGirr, Product Manager - Laboratory Separations, Bio-Rad Laboratories.
Thermo Fisher Scientific launches technical library of LC-MS solutions for analysis of PPCPs and pesticides in water Thermo Fisher Scientific Inc has announced the availability of a new technical library of LC-MS solutions for water analysis, including application information on the detection of pharmaceuticals and personal care products (PPCPs) and pesticides. The technical library, available at www. thermoscientific.com/lcmswater, is a comprehensive and regularly updated searchable resource. “We designed the LC-MS technical library to give our customers ready access to water and beverage analysis resources that can help them improve and simplify their laboratory operations,” said Dipankar Ghosh, Ph.D., Strategic Marketing Manager - Environmental and Food Safety Solutions, Thermo Fisher Scientific. “Our innovative LCMS systems support a wide variety of applications for water and beverage sampling, from targeted and nontargeted screening to quantitative and qualitative analyses. The Thermo Scientific EQuan MAX LC-MS solution is ideal for quick and easy detection of pesticides and PPCPs in surface and drinking water, reducing the time required for sample preparation while delivering the sensitivity and selectivity needed to identify analytes of interest.
Life Technologies presents revolutionary DNA sequencing technology Life Technologies, a global biotechnology company operating in India as Invitrogen BioServices India Pvt Ltd presented its unprecedented next-generation sequencing product Ion Torrent Personal Genome MachineTM (PGM) at the Innovation Update Forum. Ion PGM improves the existing decoding equipment by replacing the complex optical modules with a simple semiconductor chip. The result is a sequencing system that is simpler, faster, less expensive and
20
more scalable than other sequencing technologies in current market. PGM is featured with value, speed and accuracy. The single-day workflow -- from library preparation to data analysis is now the fastest in the next generation sequencing arena, at eight to nine hours depending on the read length required. The PGM™ system’s accuracy has improved by an order of magnitude since it was launched six months ago.
“Given the low cost and speed of analysis of the Ion PGM, Life Technologies is hoping to ‘democratise’ DNA sequencing, which has been so far a fairly expensive, time-consuming technique and restricted mainly to basic research labs. Given its ability to produce large amounts of DNA sequence data in a short period of time, we are hoping that it leads to mass adoption of this technology by scientists of every stripe and persuasion.” said Devashish Ohri, Managing Director, Life Technologies, South Asia.
Modern Pharmaceuticals I November 2011
Technology Transfer
Technology Offered As part of our endeavour to spread the technology culture, this section provides a means to promote and facilitate exchange of select technologies. We strive to bring together suppliers of such technologies with suitable users for negotiations and industrial collaboration. Natural preparation for anxiety relief A company offers food supplement in the form of tablets that effectively relieves mild to moderate anxiety problems. The ingredient is an herbal extract, which has been scientifically proved for its efficacy. Efficient decrease of anxiety symptoms, quick onset of action and no side-effects are reported to be the advantages of this product. Moreover, this product has already been launched in the American market. Areas of application Pharmaceutical industry Forms of transfer Equipment supply Anti-ulceritic APIs An Indian company offers anti-ulcer drugs like omeprazole, pantaprazole, omeprazole sodium,
omeprazole magnesium and esomeprazole magnesium for operations in manufacturing processes. Areas of application Formulation industries Forms of transfer Consultancy
filter media cleaning equipment with drying system. It consists of air wash, water wash and drying facilities. Areas of application Filter media cleaning Forms of transfer Joint venture, equipment supply
Clorsulon and its intermediates An Indian company offers clorsulon, a highly potent anthelmintic drug, which is administered to de-worm the intestines of sheep and cattle. Areas of application Pharmaceutical industry Forms of transfer Consultancy
Herbal formulation for psoriasis and eczema An Indian company offers an innovative herbal formulation that has the ability to control & cure psoriasis and eczema within one month of application of the formulation. Areas of application Herbal medicine Forms of transfer Joint venture, technical services, technology licensing
Filter cleaning system An Indian company offers an automatic
Technology Requested IV fluid manufacturing as SME An Indian company needs new and good technology to start manufacturing of IV fluids. Areas of application Medical technology Forms of transfer Technical services, others Disposable Syringes An Indian company is interested in cost-effective production line for disposable syringes for both ribbon and blister options.
Areas of application Medical industry Forms of transfer Others Biotechnology for wastewater treatment system A Thailand-based company, a wastewater service provider, is involved in the R&D of new technology for water, wastewater and waste treatment. It requires new ideas related to technology for developing its strength in the field of wastewater; which includes cleaning canals,
removing sediments from waterways, biogas, microbiology detector. Areas of application Biotechnology, engineering Forms of transfer Consultancy Calcium gluconate An Indian company requires the technology to manufacture calcium gluconate. Areas of application Pharmaceutical industry Forms of transfer Technical services, project reports, others
Information courtesy: Dr Krishnan S Raghavan, In-Charge, Technology Transfer Services Group, United Nations - Asian and Pacific Centre for Transfer of Technology (APCTT), APCTT Building , C-2, Qutab Institutional Area, New Delhi 110 016, Tel: 011 - 2696 6509, Fax: 011 - 2685 6274, Email: krishnan@apctt.org, Website: www.apctt.org, For more information on technology offers and requests, please log on to www.technology4sme.net and register with your contact details. This is a free of cost platform provided by APCTT for facilitating interaction between buyers and seekers of technologies across the globe. After submitting technology offer or request to this website, you are requested to wait for at least two weeks for receiving a response from a prospective buyer / seeker through this website, before contacting APCTT for further assistance.
Share Your Technology Propositions The mission of Modern Pharmaceuticals is to spread the technology culture. We offer you an opportunity to participate in this endeavour by publishing the best technology ideas. Technology developers/sellers are invited to furnish the techno-commercial details (with environmental benefits, if any) for publication in the Technology Transfer column of Modern Pharmaceuticals. R&D organisations, technical consultancy organisations and individuals assisting small and medium enterprises may send the relevant literature, indicating the scope & services and the areas of specification. Contact: Modern Pharmaceuticals, Infomedia 18 Limited, ‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W), Mumbai 400 028. Tel: 022-3024 5000, 3003 4679 Fax: 022-3003 4499 Email: mmedit@infomedia18.in
22
Modern Pharmaceuticals I November 2011
Dr Conversation In T S BalganeshWith: Dr T S Balganesh
‘AstraZeneca has held hands of Indian scientists for more than 10 years’ …says Dr T S Balganesh, Vice President, iScience Bangalore, AstraZeneca India Pvt Ltd. Trained as a medical microbiologist, Dr Balganesh obtained his PhD from the University of Calcutta, India, working on ‘Transmissible drug resistance in Vibrio cholerae’. He obtained his post-doctoral training at the Brookhaven National Laboratory in Long Island, New York, US and at the Max Planck Institute for Molecular Genetics in West Berlin, Germany.
Chandreyee Bhaumik
24
Modern Modern Pharmaceuticals Pharmaceuticals I November 2011
Dr T S Balganesh Your journey with AstraZeneca and how has the company grown? I had joined what was then Astra in 1987 and led the group on diarrhoeal diseases, during which the group focussed on elucidating the structure activity relationship of enterotoxins as well as developed diagnostic procedures for identification of the relevant pathogen in appropriate clinical samples. In 1990, the Bengaluru unit and Astra Sodertalje embarked on a joint programme towards developing novel antibacterial drugs and I led the programme on identifying novel inhibitors of the peptidoglycan transglycosylase. The responsibility for this drug discovery programme was transferred to Bengaluru in 1995. At this time, I also took over the responsibility for the pre-clinical activities of Astra, Bengaluru. Following the merger with Zeneca in 2002, I was appointed as the Head of Research and led the evolution of the TB programme over the last 10 years. If I have to sit back and say what AstraZeneca had invested in India, I would say that AstraZeneca has held hands of Indian scientists for more than 10 years. They have built a culture of drug discovery. There was hardly any drug discovery in India, and even today there are few pharma companies doing it. If today we can do drug discovery, it is because AstraZeneca has believed in the talent in India; that people over here have the potential to become mature drug discoverers of tomorrow. It takes a long time to build drug discovery and only if two partners are equally aligned one can see a win-win situation.
How important is ‘innovation’ in R&D? The crux of R&D is innovation. With time, the education system has recognised that innovation comes when different people sit together and discuss about a common problem and that is the culture that we need to build.
Your plans and strategies for growth. By 2014, 25 per cent of our revenue should come from the emerging markets. The question is how we achieve that. We
November 2011 I Modern Pharmaceuticals
have invested heavily in R&D in India and China. And now what we need to do is to look at the medical need in these countries.
that our work respects IP as everyone does and this is a strong component for us. For our industry, one of the main drivers of innovation is IP rights.
How can we tackle brain drain in India?
What is the recruiting policy in AstraZeneca?
While I agree there is brain drain I also believe that there is a whole climate of opportunities that are bringing people back. It is driven by job opportunities and culture. Therefore, we should see what is the most that we can do to bring people back and I think that is a big challenge. This is a matter of individual choice. There are a lot of people abroad who want to come back to India. Thus, we need to see what are the issues that need to be taken care of if we have to address the root cause of brain drain. Another important factor is that we have not been able to brand our country much. The branding has to happen in a very realistic fashion: branding in terms of opportunities, in terms of culture, innovation.
The education background that we are looking in the candidates depends on the areas for which we are recruiting. We have to be sure that the people we recruit have strong fundamental knowledge. And secondly they should have aptitude along with the attitude to work in teams. Primary domain knowledge for the fields should be there and the education system should inculcate the same.
Quick Picks Family- Wife and son Favourite pastime- I am a big fan of Amitav Ghosh. I have bought ‘Rivers of Smoke’ but not read it yet. Last book is ‘Sea of Poppies’. I love reading historical fiction.
Views on the Indian education system in this field. We tend to burden ourselves with the theoretical aspect of education. One brings in all that has happened in the last 5 years, and in the last 5 years you might have proven something that was there in the last 10 years, and is of no relevance today. But one does not remove that and continue to include everything. So, that has to change. The second thing that has to change is that an engineer must be able to go and study biology, a biologist must be able to study chemistry, and someone from chemistry must be able to study microbiology. Today, one has to have the feel of everything and that will bring a change in real sense of the term.
Message to the present generation What is next in pipeline? For the past 3 years, we went from a pharma company to a biopharmaceutical company. AstraZeneca thinks of both big and small molecules. It puts a lot of accountability on the drug discovery. These are fundamental changes on our strategy at AstraZeneca as a pharmaceutical, and I believe that these changes are also reflected in our R&D approach.
Intellectual Property Rights (IPR) and its importance. AstraZeneca has clear policies in relation to IPR. Our respect to follow IP is same irrespective of whether we are in India, Brazil or the US. We have to make sure
I would like to share a story in order to convey my message. Two youngsters decided to challenge a sage that everybody knew was extremely knowledgeable and wise. They took a bird in their hands and hid it behind them. They asked him whether it is dead or alive. If the sage says it is alive they will kill it and show him that it is dead and if the sage says the other way they will do the reverse. But, what the sage said was ‘it is all in your hands’. And this is what I believe. We hardly had anything compared to what is available today. It is indeed in the hands of the young generation and it totally depends on them whether they make it or break it. (chandreyee.bhaumik@infomedia18.in)
25
An invite that rewards as well...
Dear Reader, ‘Modern Pharmaceuticals’ solicits original, well-written, application-oriented, unpublished articles that reflect your valuable experience and expertise in the pharmaceutical industry. You can send us Technical Articles, Case Studies and Product Write-ups. The length of the article should not exceed 3000 words, while that of a product write-up should not exceed 200 words. The articles should preferably reach us in soft copy (either E-mail or a CD). The text should be in MS Word format and images in 300 DPI resolution & JPG format. The final decision regarding the selection and publication of the articles shall rest solely with ‘Modern Pharmaceuticals’. Authors whose articles are published will receive a complimentary copy of that particular issue and an honorarium cheque. Published by Infomedia 18 Limited, ‘Modern Pharmaceuticals’ is the leading monthly magazine exclusively meant for producers and user fraternities of the pharmaceutical industry. Well supported by a national readership of over 80, 000 and our strong network of 26 branch offices across India, this magazine reaches out to key decision makers among the Indian manufacturers of pharma products, machinery and allied sectors. Brought out in association with Hong Kong-based Ringier Trade Media Ltd (one of the world’s largest trade publishing houses with more than 200 special interest titles and offices in every major country), it ensures that advertisers are able to promote their products and services across the globe at no extra cost. So get going and rush your articles, write-ups, etc… Thanking you, Yours sincerely,
Manas Bastia Senior Editor Infomedia 18 Limited ‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W) Mumbai 400 028 India
D +91 22 3003 4669 T +91 22 3024 5000 F +91 22 3003 4499 E manas@infomedia18.in W www.infomedia18.in
Special Focus
Pharma machinery Single-use pharma technology Optimising on the cost and time beneďŹ ts ................................................ 28 Advances in tablet coating machine Knowing the nuances ............................................................................. 32 Interface Rajesh Shah President, Indian Pharma Machinery Manufacturers Association (IPMMA) ............................................................................ 36 Roundtable Does India need an institute/course specialising in pharma man ufacturing? .......................................................................... 37
November 2011 I Modern Pharmaceuticals
27
Special Focus: Single-use pharma technology
Optimising on the cost and time benefits With automation and advancement picking pace in pharma machinery manufacturing, manufacturers are gradually realising the importance of single line of operation. It saves time and space; the two vital aspects of any industry.
Chandreyee Bhaumik
A
long with the extensive growth witnessed by various pharma companies, pharma machinery manufacturers are also advancing themselves in order to meet various and diverse challenges of pharmaceutical industry spanning worldwide. Most of the leaders in the field are looking towards advanced markets like the US and Europe for their products. According to several estimates, the Indian pharma machinery manufacturing sector constitutes around 5-7 per cent of the global market in value terms.
28
During the 1960s and early 70s, the pharma industry in India was heavily dependent on imported machines from Europe for its processing and packaging needs. The few major foreign companies that supplied the machinery were Aeromatic, Fete, Glatt, Hassia, Hofliger & Karg, Kilian, Manesty, Sparkler, Stunk and Zanasi. However, the mid-70s saw the country going through a severe shortage of foreign exchange. Thus, the Indian government introduced high import duties and restrictive import licensing policies, which resulted in steep rise in prices of imported machinery. Therefore, pharma companies
were compelled to look elsewhere for their machine requirements, encouraging Indian engineering enterprises to manufacture machines locally. This was perhaps the only route for the pharma industry to enhance production and cater to the increasing demands of the domestic market. The scenario was not all congenial and this was a challenging opportunity for the Indian small-scale engineering companies.
Calling for integration An increasing number of foreign pharmaceutical machine manufacturers have recognised India’s achievements and evolution in the industry. Indian machines are manufactured and used in accordance with international standards. This is one of the many reasons that India has the most FDA-approved facilities in the world. Pharma machineries made in India are installed at FDA-approved manufacturing facilities in the US, Australia, Africa, etc, since they meet international standards and parameters. These countries mandate proper validation of the products. Strict quality standards are adopted by pharma machinery manufacturers in India. This has helped many Indian companies to enter into tie-ups with the companies overseas. Further, the machine manufacturers are upgrading themselves by investing in knowledge. Several pharmaceutical machinery manufacturers are regularly visiting various countries to observe and learn about the latest developments in technology in order to improve their production line. In addition to this, there are other visible trends that further reflect the commitment to excellence of Indian machinery manufacturers. Gradually, the manufacturers are aiming towards adapting single use operations. Commenting on this growing trend, Appadurai A, Country Manager, HP Indigo & Inkjet Solutions, elaborates, “Conventionally, most of the process happened in different steps. The labels were printed and then the printing of batch number, expiry date and many
Modern Pharmaceuticals I November 2011
Single-use pharma technology
Today, when space is a real constraint, with such machinery, lot of space is saved.Everything can be done by one operator. Therefore, the same space can be utilised for other purposes.
It is extremely important to be aware that this does not increase investment. It is sad but mostly such preconceived notion comes from lack of information. Appadurai A Country Manager, HP Indigo & Inkjet Solutions other things took place. Everything was accomplished in 2-3 steps. But now everything is done in one go.” He further adds that this development has helped in reducing the cost. He emphasises, “Now there is no need for storage, thus saving the storage cost.” As one is moving towards single use operation, time is also reduced significantly. He says, “Now, same amount of work takes almost less than half the time as before. Thus, there is a considerable increase in the productivity of the entire process.” According to Raj K Menon, Owner, Karishma International, pharma machinery is moving towards single line of operation. He elaborates, “With machinery like monoblock the processes have now become more compact. Earlier processes such as filling, capping etc were done in various steps but now everything can be done with the help of one machine.” Discussing the advantages derived out of these machines, he says, “Today, when space is a real constraint, with such machinery, lot of space is saved. Everything can be done by one
Factors facilita ng the technology Increasing number of firms are opting for ISO approval Manufacturers are importing proto type machines CE approval for products is being sought Firms are going in for collaborations and technology transfer Manufacturing units are steadily expanding to meet the rising global demand
30
Raj K Menon Owner, Karishma International
operator. Therefore, the same space can be utilised for other purposes. The operation time is also less , thus providing optimum utilisation of both space and time.”
that specialise in single use pharma technology. The continous interactions between the pharma companies and the pharma machinery manufacturers bring forth the demands and the latest trends, opportunities in this field are observed.
Not a smooth ride Machine-makers are increasingly upgrading and moving towards computerisation, using Computer Numerical Control (CNC) machines and incorporating precision instruments such as Variable Frequency Drive (VFD), Programmable Logic Controller (PLC), etc in their products to get quality output. And, in this age of advancements and developments, it seems that single line of operation will smoothen the whole process. A lot has to be done in order to harness the opportunities and leverage on them. Awareness is also a primary consideration. Commenting on the need of awareness, Appadurai opines, “It is extremely important to be aware that this does not increase investment. It is sad but mostly such preconceived notion comes from lack of information.” He highlights the need for constant seminars, discussion forums that would enhance the expertise and technical knowhow of the pharma machinery manufacturers. They would be able to participate in innovation and come up with better and logical designing. Challenges to the adoption of singleuse systems are mainly based on technical merit and feasibility or predicated on size. However, today various seminars and conferences are organised. These help in enhancing the knowledge of the people required to operate the machines. Again, there are various pharma exhibitions pertaining to pharma machinery
Containing factors Discussing the cost and the investment pattern required for such machinery, Menon avers, “Usually, in these cases, the initial investment is relatively more. The cost is approximately three times higher. However, in the long run, the cost gets recovered with the minimisation of operating costs and several such related factors.” He further adds that in India machinery for single line of operation are rampantly used. And according to him, the machines manufactured locally are manufactured at a cheaper price than the ones manufactured in Europe. He highlights, “Today, people are travelling extensively. Big teams of Indian pharmaceutical companies participate in International exhibitions. Here, they get exposed to the Japanese, Korean machines and then they want similar quality machines from the Indian manufacturers also.” Commenting on the area of concern, he says, “Speed is still a constraint as far as Indian machinery is concerned. The machines manufactured overseas have high speed of operation. Thus, this is an area that needs special consideration. However, Menon is hopeful. He signs off saying, “Continuous seminars and exhibitions will help in increasing the knowledge bank.” (chandreyee.bhaumik@infomedia18.in)
Modern Pharmaceuticals I November 2011
Special Focus: Advances in tablet coating machine
Knowing the nuances Tablet coating is one of the crucial aspects of the manufacturing process. It helps in taste and odour masking, brand recognition, improved stability, among others. An evaluation on how the process that started with sugar coating has evolved over years.
Chandreyee Bhaumik
S
ince a long time, sugar coating of pills has been providing taste masking and finish that is unrivaled in elegance, even today. With the passage of time, several polymers and plasticizers have been used for the purpose. Organic solvents have paved their way in, in a big way. The shape, size and colour that we see are all visual characteristics reflected by the core and the coating such as sugar coat, film coat, etc. According to Jignesh M Panchal, Partner, Karnavati Engineering Works, tablet coating is an extremely important phase. Many technologies are involved in this process. Thus, care should be taken to make this process an accurate one.
Changes over the years ‘Necessity is the mother of invention’ goes
32
the old adage and thus with the need to evolve came the change in the forms of tablet coating. In the early 70s, most of the manufacturers preferred film coatings that were using organic solvents. The film formers that were used for coating were cellulose ethers including ethylcellulose, hydroxylpropyl cellulose and many others. Shifting to solvent-based coatings from the initial sugar coatings had its own reasons. The new process required less time and only one part of the equipment. Therefore, soon, productivity was enhanced. However, as the world gradually comprehended the need to become more ‘environment friendly’ there were new concerns and challenges to face. Coatings are required for many reasons like tablet appearance, brand recognition, identification of taste, dosage, odour masking, improved stability, improved bulk handling and many other related
aspects. For tablet coating it is very important to remember aspects like ‘dose’, ‘distribute’ and ‘dryness’. Discussing the importance of tablet coating, Pradeep Tamhane, Managing Director, Wincoat Colours and Coding Pvt Ltd, opines, “Coating is the last phase after which it goes for packaging. Involving the accurate technology and chemistry is essential. Physical chemistry, colour chemistry, regular chemistry is needed.” Problem with the application of aqueous coatings was temperature processing While solvent-based solutions required less time to dry, aqueous solutions took much more time. Steps were taken to control these factors by adding heat and limiting the air flow but it was of not much effect. Then, manufacturers turned to side vented vans where the water evaporated much more efficiently. This was easy because most of the traditional film formers were water soluble. Therefore, soon aqueous solutions assumed a huge dimension. Gradually, in order to lower stickiness in the tablets, the focus shifted towards solid concentration. Polymers like polyvinyl pyrrolidone, polyvinyl alcohol and many others. These alternative polymers provided gloss and added flexibility properties.
Advancements There are various ways of coating a tablet. Earlier, it was sugar coating and the process is rampantly in use. Wurster coating is another method. It involves a cylindrical chamber in which the tablets are suspended and a coating solution is introduced. Fluid bed coating is another common process. And dry coating is another method of making a tablet within a tablet. However, the most important method of tablet coating is film coating. Over a period of time, film coating has gained a relative prominence over the other methods. Initially, the liquid component of coatings was a volatile solvent, like alcohol or methylene chloride or many other quick drying substances. However, though solvent-based coatings had their advantages, there were various challenges. Problem in handling,
Modern Pharmaceuticals I November 2011
Advances in tablet coating machine
Improper application of the solution, poor design of the tablet and many other factors cause the coating to fill in the lettering or logo on the tablet. This harms the consistency of the tablet.
Many technologies are involved in the tablet coating process. Thus, care should be taken to make this process an accurate one. Jignesh M Panchal Partner, Karnavati Engineering Works operator safety, odour are few of the many problems. Sometimes, they can even make the tablets smell like the solvents. Water based or aqueous coatings have replaced them but they also have their own hindrances. Thus, one must apply the coating and remove water before it hampers the integrity of the tablet. If tablet coating is consistent, the coating process is much easier. Consistency is not much of an issue for the pharma industry compared to the makers of vitamins, herbals, dietary supplements. These products use many natural ingredients that vary in moisture content, granule structure, bulk density, compressibility and many other aspects. Discussing this characteristic, Tamhane avers, “Consistency is one of the most important aspects for tablet coating. Addition of film should be uniform. Care should be taken that there is no logo breaching. In this vein, colour matching software should be developed so that consistency is not hampered. Again, it should be seen that there is no disparity in colour application. Thus, if green colour, which is a combination of yellow and blue, is applied, it should be seen that there is no separation of the two colours. Fine tuning is a must in this case.” The tablets must be consistent in porosity and hardness. They must also be free of dust. They must not break apart during the preheat cycle at the start of the coating process or even during the first few minutes of exposure to the atomized solution. Consistent hardness of the tablet enables the coating to stay onto the surface. However, if the surface of the coating is too soft the impingement of the solution can erode the tablet. On
34
Pradeep Tamhane Managing Director, Wincoat Colours and Coding Pvt Ltd the other hand if the surface is too hard, it will not allow the surface to impinge. Both these conditions occur when excessive or more coating solution is applied. Discussing the advancements in tablet coating, Tamhane says, “With time tablet coating is undergoing various changes. There are add on effects like pearl shine on the tablet. Further, ‘quick coat’ is also gaining popularity where coating time is reduced considerably.” He adds that his company coats about 100 tonnes per year.
Consistency is not much of an issue for the pharma industry compared to the makers of vitamins, herbals, dietary supplements.
Points to note There are various important factors that one needs to consider while tablet coating. Several problems occur when one cannot control factors like temperature, spray rates, pan pressure and atomisation pressure. This leads to various defects. Sometimes the coating removes a portion of the tablet. This is called ‘picking and sticking’. Further, Tamhane says, “Improper application of the solution, poor design of the tablet and many other factors cause the coating to fill in the lettering or logo on the tablet. This harms the consistency of the tablet.” One should clean and dry each component of the spraying system so that damage does not occur. Thus, it should be remembered that in tablet coating even the minutest of difference can cause a huge difference thereby harming the quality of the product.
Down the years Aqueous film coating has undergone tremendous progress in many areas. A perfect example of this is the success of applyting one-step, pigmented, enteric coatings. Initially, it was a difficult technology that one found hard to master but is now much more practical and definitely user friendly. Formulators supply this same one-step technology to other functional coating products, such as sustained-release films. Further, high speed processing has also witnessed tremendous progress. This leads to shorter life cycles and enhanced productivity.
The fascination for the gloss and special effects will invite and invent more additions to the already existing plethora of tablet coating forms. The desire to make the tablets either glossy or have matt finish, to give them the pearl effect have brought various changes in the tablet coating forms. However, in the hope to follow these, often the entire process becomes a costly affair. Often, the process is considered more of an art than a science. A balanced scientific approach that accounts for the critical components in coating systems and coating processes will enable the industry to meet new challenges. (chandreyee.bhaumik@infomedia18.in)
Modern Pharmaceuticals I November 2011
Special Focus: Interface - Rajesh Shah
‘Our machinery industry will definitely reach closer to any world class manufacturer’ ...says Rajesh Shah, President, Indian Pharma Machinery Manufacturers Association (IPMMA). He discusses the current landscape of the Indian pharma machinery segment. How is the flow of investment in this space? There is no authentic source on the statistical data of the investment in pharma machinery segment. However, being one of the essential segments of the industries and consistent development and growth patterns, pharma machinery manufacturers also have to develop and adopt new technologies that result in growth of the industry and offers good Return on Investment (ROI) as compared to any other machinery industry.
Chandreyee Bhaumik The current market scenario for pharma machinery industry. Is India at par with the other countries? The Indian pharma industry is doing well at the domestic and international level and many pharma companies are expanding their wings worldwide either by acquisition or Joint Ventures ( JVs) for marketing or technical support. And the pharma industry is expected to make continuous growth. The performance of the Indian pharma industry in context with the world market, is promising and growing. These performance and expansions in the Indian pharma industry have direct growth effect on the Indian pharma machinery and allied industries. Several leading players in pharma industry are marketing their products directly or producing them under a licence and exporting worldwide Therefore, they have to upgrade their facility by introducing high-tech machinery. What have been the recent advancements in pharma machinery segment? Looking at the ongoing advancements taking place in the research, formulation and development in the Indian and global pharmaceutical industries, the pharma machinery manufacturers also have to develop and offer cutting edge technologies to comply with the requirement of the industry.
36
Many pharma machinery companies have introduced automation in their machines to compete with European manufacturers by incorporating latest IT solutions available, which in turn helps to boost quality, production and proper documentation. Recently, due to the Directorate General of Foreign Trade (DGFT) notification with a time frame, many leading players have developed a complete solution for track & trace system, which will be required by all leading manufacturers who are exporting their products. Several machinery manufacturers have started entering JV or technical support from leading players in the world to upgrade their existing technologies.
What are the issues faced by this segment? Pharma machinery faces a challenge from Chinese manufacturers with respect to cost competition. However, Indian industries always overcome such challenges using the best available components, hardware and software. Similarly, we have to compete with the European manufacturers, who offer an excellent quality, but they are expensive. Hence, the Indian pharma machinery manufacturers have started upgrading their manufacturing facility by introducing high-tech production machines for better finishing, timely delivery with consistent quality. Where do you see the industry in the next five years? With the present re-engineering process going on in the industry, it will definitely reach closer to any world class manufacturer. (chandreyee.bhaumik@infomedia18.in)
Modern Pharmaceuticals I November 2011
Special Focus: Roundtable
Does India need a specific institute/course specialising in pharma manufacturing? Although there are several pharmacy colleges in India, there is a huge dearth of institutes/courses that will impart technical knowledge about pharma machinery. In this scenario, an institute catering to specific needs seems a must. Experts discuss the ‘yes’ and ‘no’ of the proposal. Chandreyee Bhaumik
Praful Naik Chief Scientific Officer, Bilcare Research, Bilcare Ltd
S Thyagarajan President, Indian Analytical Instruments Association
Dr Ganapathy Ramakrishnan, President, Chromatographic Society of India
There is no need for a separate pharma institute that would solely impart knowledge about pharma machinery. We require a vocational course that will aim to offer professional certificate or a degree. Today, there are so many operators in pharma companies who do not have a professional degree in particular; a vocational course is extremely required. Additionally, there can be further training and upgradation in order to make the knowledge extremely segment specific. Regulatory bodies like Pharmacy Council of India should come up with a course that will provide the knowledge along with an appropriate certificate that holds relevance in the industry. Freshers can also undergo this programme as it really helps in laying the knowledge foundation, and mandatory internships can be a part of the curriculum.
There is no need for such an institute in particular. Today, we have come a long way where all sorts of knowledge is available. About 20-30 years ago we had to depend on an institute for expertise and knowledge. But, today the companies can get into any form of Joint Venture ( JV ) and share the mutual knowledge. Leveraging on this kind of symbiotic knowhow is what is required. Countries such as China is following this kind of trend and improving immensely. A particular institute is only suitable for the basic fundamental training and the knowledge on R&D. And today JV is possible in all the quarters; hence according to me; JV is much a preferred option than an institute.
A pharma college should encompass everything from production, manufacturing to the ultimate packaging. Any B Pharm college takes care of this entire value chain of the pharma industry. Further, there are colleges on pharma technology that cover the technical aspect of the industry. In fact, pharma colleges should take part in ‘industry attachment’ programmes that will encourage frequent education trips to pharma companies. The students will get a hands-on feel about the job.The relation between university and industry needs to be strengthened. Though there are several challenges like regulations, hygiene and others that do not allow the students to visit the industry often. But constant efforts should be made so that the interaction becomes strong.
Editorial take
Looking at the views of these experts, it seems that there should be a specific vocational course that offers the technical knowhow along with appropriate certification. Additionally, this course should be updated with the latest industrial requirements.
November 2011 I Modern Pharmaceuticals
37
Photo by: Joshua Navalkar
Facility Visit: Kewaunee Scientific Corporation
Leaders of technical guidance and labs in India The best way to ensure that scientists as well as research laboratories do not get contaminated and the facilities provided are world class is by setting up a proper high quality infrastructure. Kewaunee Scientific Corporation steps in here for help. Jasleen Kaur Batra
T
he developing pharma industry with the increasing research and discovery needs require safe, flexible and highly functional labs that addresses issues like proper airchanges, consistent utility supply and much more. Setting up a new or renovating an existing R&D or quality control laboratory requires investment of time and a huge capital. What most companies seek is high quality, costeffectiveness and supreme quality set up while establishing their laboratories. Kewaunee offers these services to all such companies who requires a solution while setting up laboratories. It is the premier supplier of total laboratory solutions serving the US, Latin
38
America, African, Asian and Middle East markets. Its main focus is to provide world class laboratories to private industry, academia and government facilities. Speaking about the unique capabilities of the company, B Sathya Murthy, Managing Director, Kewaunee Scientific Corporation, says, “When a client sets up a project he/she looks at important things - best of cost, world class quality and timeline. For them to have all these combinations at one place, to have a company that understands their requirements and delivers the project in the way they want it, is an added advantage. Kewaunee has the best of all worlds like the in-house turnkey engineering capability, a proven project delivery mechanism and processes and a world class manufacturing facility to deliver the projects on time and within
the allocated budget.” He adds, “Our team first acquires basic understanding of client’s process requirements and then look at converting them to engineering reality then to delivery and project execution. There are few companies in the world who provide services for all these. If design programming and project planning is not done accurately it would lead to timeline delays and cost over runs to rectify the mistakes. All these potential project risks encourages potential clients seek companies like ours to provide a total package of service, which saves them a lot of time and money and increases their productivity by focusing on their domain forte.”
The unplanned entry Kewaunee has been around for more than 100 years, but made its presence felt in India little over a decade ago. The company was set up in the US in the year 1906 and since then it has established its name world over with high quality products and services. It is present in the field of manufacturing cabinets and safety units for pharma, biotechnology and other industries. The first time it set up an operation outside the US was in 1995 in Singapore, after which it came to India in 2000. Its road to the Indian market was unplanned. “We participated in a Global tender for John F Welsh Technology Center, GE Global R&D Centre
Modern Pharmaceuticals I November 2011
Kewaunee Scientific Corporation India at that time was growing in contract research and a number of companies were setting up such units and were trying to cut cost, hence we got a lot of projects and did not face troubles being a part of the Indian market.
There are few companies in the world that offer total in-house technical guidance and set up for labs. And we are recognised in the industry because of our expertise and quality products. Sathya Murthy Managing Director, Kewaunee Scientific Corporation
in Bengaluru and I strongly felt that India was not ready for us during that time. But winning the GE project and establishing our sales and marketing organisation was an excellent timing for our market entry into India. Our successful completion of GE project was a turning point for us and many invitations from companies started pouring in that is when we realised that the Indian market is ready for highend laboratory case work products. We have worked for leading pharma companies such as Biocon, Dr Reddys, Ranbaxy, Cipla, Watson, Teva and a number of other companies from cities like Mumbai, Chennai, Hyderabad and more,” informs Steve Vadehra, Vice President -International Operations, Kewaunee Scientific Corporation. The company set up its operations in Bengaluru in 2000 for sales and project functions; in 2002 it set up the first assembly line unit, and started full fledged manufacturing of Indian specific products in 2008. Kewaunee did not face too many hurdles on their path of setting up their plant in India as a number of companies were in line to work with them besides the high cost. “I was curious to know why the companies were not affected by the high cost and were ready to pay as much for our services. Gradually, I understood that the
Accredita ons Certified by Integrated Management System (IMS) Quality Management System ISO 9001- 2008 Environmental Management System- ISO-1401- 2004 Safety OHSAS- 2008 Factory Mutual (FM) Scientific Equipment Furniture Association
November 2011 I Modern Pharmaceuticals
Steve Vadehra Vice President, International Operations, Kewaunee Scientific Corporation
companies wanted top quality products, which at that time were being imported from the US. The quality of raw materials and products we use is of high quality. India at that time was growing in contract research and a number of companies were setting up such units and were trying to cut cost, hence we got a lot of projects and did not face troubles being a part of the Indian market,” says Vadehra.
Spreading wings Today, Kewaunee’s manufacturing unit in Bengaluru with state-of-the-art manufacturing facility provides laboratory furniture, fume hoods, and complete laboratory set ups on turnkey basis. Approximately 150 employees are working here and it caters to more than 200 companies in India. Besides India, it is active in the Middle East, Dubai, Abu Dhabi, South Asia, China, UAE, Taiwan, Iraq. The company supports many state governments in their initiatives to set up bio tech parks (Kewaunee is a partner in this project and has already set up a few laboratories for them). It has been a part of few government projects since 2002 like the TICEL Biotechnology Park in Chennai, Punjab Biotechnology park in Chandigarh and has set up labs for IITs, IISC, Delhi University among others. “The reason behind setting up a unit in India is because the specifications and quality check measures in the US are different from that in India; hence we have our own team design, technical, engineering and marketing team in Indian. We have supported the local Contract Research Organizations (CRO’s) and other companies to set up their laboratories and provide a world class lab from one source,” avers Vadehra.
Strong forte Few companies globally provide technical assistance on how to set up a laboratory or a
quality control unit. For start up companies this guidance is of supreme importance. According to Murthy, “There are few companies in the world that offer total in-house technical guidance and set up for labs. And we are recognised in the industry because of our expertise and quality products. What we are able to accomplish today has not come to us easily and we have proved our worth with the quality of work consistently, which is why we have a name in the industry.” The expert team visits the client’s company to understand the needs, document them and program the process to engineer the project. After many interactions with the actual end users all the inputs are converted to basic concept drawings then to detailed workable engineering drawings. The client experiences a high technological interface through the 3D visuals and walk throughs, which would enable them to take decisions faster. Kewaunee is in the process of launching a few new products like safety cabinets, flexi labs (with portable systems and equipment) and 20-20 labs, where they would set up a lab within the span of 40 days. All these services are still new to the Indian market as not many companies have come forth to provide such a facility. Kewaunee has a trail of ideas of innovation that are currently under the cover and would be revealed in the times to come. They have certainly marked great achievement for themselves for being the only multinational company manufacturing laboratory case work in India. “We do not want to stop here; we are extremely happy with the outcome so far and we would try our level best to bring in more technology in India so that we can offer better services to our clients. This is definitely just the beginning and we have a long way to go,” signs off Murthy. (jasleen.batra@infomedia18.in)
39
Insight & Outlook
Pharma raw materials High potency APIs market in India A foolproof shot?.................................................................................... 42 Indian market for penicillin Needs a major push ................................................................................ 46 Interface K V Ranga Rao, Executive Director, Bulk Drug Manufacturers Association (BDMA)........................................ 52 Roundtable Will high import duties impact trade relations between India and China? ...................................................................... 54
November 2011 I Modern Pharmaceuticals
41
Insight & Outlook: High potency APIs market in India
A foolproof
shot?
Asia-Pacific is encountering the highest growth in Active Pharmaceutical Ingredients (APIs) and high potency APIs (HPAPI). Due to its efficacy and performance it is beginning to capture the market. India too is in the league, but the market is still at a nascent stage and more investments will drive it higher. Titash Roy Choudhry
A
dosage form of a pharmaceutical drug has an Active Ingredient (AI) that is biologically active along with an excipient, which makes the tablet or the liquid. API has been defined in the US Food & Drug Administration (USFDA) document Q7A on Good Manufacturing Practices (GMP) Guidance for API, as “Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.” The API market worldwide is experiencing high growth rate especially
42
high potency APIs. And it is this segment of the market that has become the fastest growing market segment in the pharma market.
Decoding HPAPI Substances where the therapeutic dosage is very low, generally in micrograms to a few milligrams can be termed as HPAPI. “The potency or toxicity of these compounds are categorised on performance-based Occupational Exposure Limits (OELs). The lower the limit, the more potent the substance. Thus, ‘potent compounds’ are compounds with OEL between 30 ng/cubic metre and 10 mcg/cubic metre, while highly potent compounds are those with OEL less than 30 ng/cubic metre,” informs Dr Ravi Sobti, Pharmaceutical Professional. They are highly effective at much smaller dosages and hence, much more efficient in curing some diseases than other non-potent APIs. The
healthcare standards in India are growing fast as the economy is experiencing better growth, while the acceptance of and adaptability towards new drugs and therapies is also growing. As a result, the region shows the fastest growth rates in the high potency market. Then, there is also a growth of targeted therapy approach in the treatment of various disease, be it cardiovascular disease or cancer or others; APIs with their selective targeting property are becoming more successful in treating these diseases. The major therapeutic application of these compounds is in oncology drugs. “In HPAPI manufacturing companies basically consider oncology products, some hormonal products like steroids, but the main driver for HPAPIs today are the oncology products. It is one therapeutic area that is growing faster than any other therapeutic group and the main driver of the global HPAPI market. Cancer related to any part, be it lung or prostate there is a lot of research going on in the said area and HPAPI has been able to reduce the suffering of cancer patients to some extent,” states Dr Sobti. One of the major growth drivers of HPAPI is anti-cancer drug, since selective targeting property of HPAPI is widely used in the treatment of cancer. High potent anti-cancer drugs are effective as they target only the cancerous cells, thus minimising the drug’s exposure to healthy tissues. The market for oncology drugs in Asia Pacific is growing at a rate close to 20 per cent. With the rise of incidences of cardiac disease or cancer patients the demand for HPAPI is also increasing. “Slowly the disease burden is shifting from infectious diseases to more lifestyle-related diseases and that is a major driving force for HPAPIs. The market of HPAPI will continue to rise in the coming years,” says P D Sheth, Secretary, SEARPharm Forum. The usage of HPAPIs is increasing in other fields like cardiovascular, central nervous system and others.
Landscape & opportunities The total HPAPI market in 2010 was around $ 57 billion and was pegged to be
Modern Pharmaceuticals I November 2011
High potency APIs market in India
There is a significant barrier to enter the HPAPI sector because of the high cost of installing HPAPI facilities. These facilities have significant handling issues. Dr Ravi Sobti Pharmaceutical Professional growing at the rate of 7 per cent, whereas the overall pharmaceutical market growth is not more than 3 per cent since more generic compounds are coming up. So the HPAPIs market worldwide is encountering higher growth rate than the pharmaceutical market as whole. The market leader of HPAPI today is North America with a global share of almost 46 per cent, followed by Western Europe with a share of around 35 per cent. Asia-Pacific region has a share of 9 to 10 per cent out of which Japan has the major share. The Indian and Chinese markets are closely following Japan with high growth rates. Asia Pacific is also the fastest growing API market in the world. The AsiaPacific API market grew consistently at a Compounded Annual Growth Rate (CAGR) of 6.7 per cent from 2005 to 2010 and is expected to grow at a CAGR of 9.6 per cent from 2010 to 2016. “When it comes to production of APIs, there is a lot of competition between countries such as India, China and others, but same is not the case for HPAPIs. For HPAPI we see the majority of the share being with North America and Europe since there is a lot of manufacturing guidelines and restrictions that needs to be followed for manufacturing HPAPIs,” says Dr Sobti. Though the demand for API is high and Asia-Pacific region holds a prominent share in the world API market, yet manufacturing of HPAPI is not easy. “There is a significant barrier to enter the HPAPI sector because of the high cost of installing HPAPI facilities. These facilities have significant handling issues due to the highly potent compounds. The major cost is associated with the
44
Slowly the disease burden is shifting from infectious diseases to more lifestylerelated diseases and that is a major driving force for HPAPIs. PD Sheth Secretary, SEARPharm Forum
specialised containment needed to ensure that employees and their environment are protected from exposure. This requires (a) room pressure differentials with the main HPAPI-handling area at negative pressure to surroundings (b) airlocks and vestibules around manufacturing and laboratory spaces to provide gowning and degowning areas and proper pressure differentials (c) HVAC systems designed for single-pass air – no return with temperature, humidity and particulate controls (d) misting showers as part
High costs and regulations of HPAPI manufacturing, have insulated the US and Europe market from competition.
of degown and exit vestibules to rinse personal protective equipment and gowning prior to removal (e) filtration and capture of contaminants with safechange filters,” informs Dr Sobti. And such high costs and regulations with HPAPI manufacturing, have insulated the US and Europe market from competition. “HPAPI global market is relatively uncompetitive and the demand is more than the supply and this trend is likely to continue for another five years or so,” believes Dr Sobti. But still there are companies in India who are taking the risk and entering
into the HPAPI market, seeing the high growth rates. “There is a company named Aptuit Laurus that has started manufacturing HPAPIs and few others who are taking lot of interest in setting up these facilities for HPAPIs. HPAPI is an excellent market for growing countries like India,” says Dr Sobti. Sheth also believes that there is future growth potential in this market and India should invest in HPAPIs. Carbogen Amcis, a part of the Indiabased Dishman company, has set up one of the world’s largest HPAPIs facilities at Bavla, Gujarat. “Out of the $ 57 billion global market, India’s share will not be more than $ 4 billion, but it is growing. HPAPI becomes an excellent growth opportunity for countries like India where you have all the necessary manpower required, and the only focus should be developing good containment facilities, having special equipment, handling facilities, containment technologies for proper manufacturing and storage facilities,” Dr Sobti avers. This market is dominated by the innovators patented high potency drugs. But contract manufacturers are entering the area where compounds are coming off-patents. The disease burden is not slowing down, instead it is increasing and with increased cancer patients the use of HPAPI will also increase in the coming years. Hence, India needs to invest in HPAPI more, “And more investment in this market by Indian companies will boost the local market as well as the export market by creating more competition worldwide,” says Sheth. (titash.choudhury@infomedia18.in)
Modern Pharmaceuticals I November 2011
Insight & Outlook- Indian market for penicillin
Needs a major push
The importance of penicillin had become evident long while ago and responding to that the Indian government had taken initiatives to manufacture it. But with passing times, the scenario has changed and today India is almost entirely dependent on imports of penicillin to meet its domestic demand. Titash Roy Choudhry
T
he world economy is undergoing a massive upheaval, with emerging economies taking over the already existing markets. Penicillin has always been an integral part of pharmaceutical market as it is used both in formulations and intermediates. This pharma raw material has grown in importance and a lot of changes have swept the global penicillin market scenario. These changes
46
have also affected the Indian market that had started with positive efforts but dwindled with years leading to a grim present situation. Penicillins are powerful anti-microbial substances extensively used in the treatment of various infectious diseases. Of these, Penicillin-G and Penicillin-V are the two penicillins that were produced by submerged aerobic fermentation techniques for the first time in the pharmaceutical industry in 1944, opening ‘the antibiotic era.’ ‘Penicillin G is used to make antibiotics like amoxicillin, ampicillin and others. It is the starting
material used for this antibiotic using fermentation process,” says Naresh Gupta, President, API and Global TB, Lupin. Though Penicillin G and V are still important pharmaceutical drugs for the treatment of various infectious diseases, their use as drugs is decreasing, since the newer semi-synthetic penicillins and cephalosporins are being used more.
Indian market dominated by imports The present scenario in India is very bleak, with virtually no production of Penicillin G in India. Its use as a raw material for antibiotics has increased in the recent years and along with it the market dynamics have also changed. In the 1950s India had entered the penicillin market, which was then dominated by countries such
Modern Pharmaceuticals I November 2011
new busIness opportunItIes invites you to
CUT HERE
InvItatIon
CHENNAI 8 - 11 Dec 2011 Chennai Trade Centre 10 am - 7 pm
Engineering Expo organised by Infomedia18 is one of the engineering industry’s biggest events in country. The 2010-11 edition of Engineering Expo saw business transactions worth over Rs. 161 crores. Launched in Ahmedabad in the year 2002, the event today boasts of a fabulous visitor turnout. The Expo is a preferred destination for SME’s and manufacturing & engineering companies to transact, network, tie-up and exchange ideas for the growth of the industry.
Exhibitor Profile Auto & Auto Components | Light & Medium Engineering | Chemicals & Allied Products | Electrical & Electronics | Hydraulics & Pneumatics | IT Products & Services | Automation & Instrumentation | Material Handling Eqpt | Packaging Machinery | Wires & Cables | Machine Tools & Acc. | Pipes & Fitting | Plastics & Polymers | Safety & Security | Process Machinery & Eqpt | Testing & Measuring Instruments Brought to you
Online Media Partners
CUT HERE
Supported By
For Further Details, Call Varsha + 91 98195 52270 Or Email engexpo@infomedia18.in
Indian market for penicillin
If China decides to stop the supply of Penicillin G, India will be at a complete loss since it does not have the manufacturing capabilities to meet even a fraction of the domestic demand. Naresh Gupta President, API and Global TB, Lupin as Japan, Mexico and Europe. India had set up various manufacturing plants for penicillin. But with emerging markets and change in the world economic balance, China gradually took over most of the production of penicillin in the world. “This raw material that is used for the production of antibiotics is only produced at a large scale in China today. There is no manufacturing of Penicillin G in Mexico or any other country, so China can be termed as the sole manufacturer of this raw material,” says Gupta. Today, almost the whole world is dependent on China for supply of Penicillin G and reasons that created this scenario as pointed out by Gupta are, “First, as far as China is concerned they play a large scale game and have captured the penicillin market when it was vacated by players in Mexico and Japan. Then there are various subsidies provided by the Chinese government, which reduces the cost of manufacturing allowing Chinese companies to sell at a far cheaper price.”
Daunting scenario “The market for penicillin as a raw material is very small, almost negligible and is mainly dominated by China. For finished antibiotics we have to depend on China for penicillin as a raw material and this dependence is giving rise to a monopoly situation where China is regulating the prices of this raw material. Every other day we here some price rises for Penicillin G and this also affects the Indian market,” says Vijay Agarwal, GM Marketing, Rajasthan Antibiotics Ltd. In India, currently almost the entire demand of penicillin is being met through imports from China. There are few private companies that manufacture this raw
50
material but their miniscule production is not sufficient. The government has taken a step back from this market and shut down all the manufacturing units that were set up in the 50s. In the 90s private companies started entering this market but they also could not compete with China in terms of pricing or cost structure. “Earlier government had given licenses to the government sector for penicillin manufacturing and later it was opened to the private sector also, where some of the big pharma companies entered into manufacturing this raw material. But many closed down since they were incapable of competing with China, while others which are still manufacturing contributes in very small quantity, thus forcing us to look outside for penicillin supply. India also does not have the infrastructure required to compete with China and this bleak situation needs to change,” says Agarwal. Today, the capacity of penicillin G production is China is much more than the world demand and so with such cutthroat competition, prices are the cheapest in China. In such a case, not only India but almost the entire world looks towards China for penicillin supply. And for India the case is more sensitive since both are emerging economies that are competing with each other and in such a situation complete dependence on China for penicillin supply is a big risk. “If China decides to stop the supply of Penicillin G, India will be at a complete loss since it does not have the manufacturing capabilities to meet even a fraction of the domestic demand,” says Gupta.
Torch-bearers required Indian pharmaceutical market has two basic components; one is the requirement
for domestic market, which is increasing rapidly with increased affordability. Second, India is a major exporter of Active Pharmaceutical Ingredients (APIs) and finished formulations, so if we look at the growth rate it will be huge but the question is how do we make that growth profitable for Indian market? With the increasing disease burden in India, antibiotics have become a way out for most of the disease. Even for a minor flu, we all are popping antibiotics at some point of time and they have become integral part of our daily health. In such a scenario the usage and requirement of penicillin is also something that needs to be addressed. “In India everything is commercialised. On top of that, the government companies that were manufacturing penicillin G earlier also closed down, due lack of technology and support from government. The government is missing the will in terms of providing support, talks are on about steps to be taken to restart the fermentation industry but nothing concrete has been done till now. The demand is there but lack of government support is making it difficult for India to compete with China,” says Gupta. Government has these factories that are lying unused and efforts should be taken to start them, even if they run in losses. “I really do not know if we can regain our position, it may be difficult to do that. But government should come in the forefront and take initiatives through providing subsidies. There are a lot of subsidy options that we can figure out and we can start manufacturing Penicillin G in the government factories and compete with China in terms of pricing and increase the technical know-how, improve the productivity over a period of time,” says Gupta. The initiatives from individual private pharma companies will come once they have the option of competing with China and that option will be provided by Indian government through subsidies. An increased dependence is going to paralyse the penicillin market of India, so efforts need to come from the government side to revive this market and help achieve some amount of self-sufficiency. (titash.choudhry@infomedia18.in)
Modern Pharmaceuticals I November 2011
Insight & Outlook: Interface - K V Ranga Rao
‘India’s pharma market is in a volatile stage, and will take some time to stabilise’ ...says K V Ranga Rao, Executive Director, Bulk Drug Manufacturers Association (BDMA). With almost 15 years of pharmaceutical expertise, Rao has seen the Indian pharma market go through some significant changes. Today, as the Executive Director of BDMA he is trying to build stronger communication between the industry players and the government. Titash Roy Choudhry Journey with BDMA and the Indian pharma market I have been with BDMA since the last three years and the journey has been smooth without any major ups and downs. The pharmaceutical market has become volatile, which has led to uptake of higher initiatives and issues to be addressed. There have been changes in the market constantly, but recently the industry has witnessed some significant ones. A major growth driver of the Indian pharma market today is the Small and Medium Enterprises (SME), and with various M&As taking place it is the SME market that is getting affected. Currently, there is no stability in the Indian pharma market because of frequent changes in legislations and regulations in order to compete in the international market. The pricing bodies in pharmaceuticals such as Drug Pricing Control Organisation (DPCO) or National Pharmaceutical Pricing Association keep on changing the rates because of the pressure of meeting the competitive market demand. Along with pricing regulations, other regulations such as environmental regulations, high labour prices and energy cost have created a phase of uncertainty since 2008. Bulk drug manufacturing in India There are various reasons which will lead to increased consumption of drugs among Indians in the coming years. First, there is a huge population growth along with increased ageing population, and this demographic change will lead to higher demand of medicines. Also, with
52
growing economy the purchasing power of average Indian is also growing. So the demand for generics will be high in the coming years and India is renowned for its generic market. But currently we are not equipped to even meet the demands of our own market. Most of the basic raw materials are being imported, almost 45 per cent of the intermediates required in manufacturing drugs are being imported, and to some extent imports are affecting the local manufacturers. Still realising the future need and growth opportunity, that by 2012 a major chunk of drugs will go off patent many local companies are entering the bulk drug manufacturing sector. Bulk drug is a red category industry that produces environmental problems, and more eco-friendly environments need to be created to help this sector grow. BDMA initiatives Our association works as an interface
between the industry players and the government, and our main task is to put forward some of the pressing issues to the government and seek their response. We have taken up several issues with the government. Almost all countries have their inspection mechanism for manufacturing units from where they are importing products. But nothing similar is being done by India, and so we proposed that India also should have an inspection body that would go to the units from where we are importing our products. Government has given a fast response to this problem by partnering with private players and initiating the process of setting up a team for inspection. We have also brought into the government notice the shortage of Drug Control officers throughout the country and they have started filling in. So as an association we have been undertaking several initiatives. Future growth potential The future growth potential in the pharmaceutical market lies with the SMEs, since they will be the driver of growth of Indian pharmaceutical market. Today SME’s contribution to the Indian pharma market is almost 40 per cent that will increase in the coming years since there will be a growth in contract manufacturing and R&D. Indian government has already allocated almost 30,000 crore to spend on SMEs in the 12th Five Year plan. Presently, the Indian pharma market is growing at 11 to 14 per cent, which has the potential of growing at 15 to 20 per cent rate in the coming years. (titash.choudhry@infomedia18.in)
Modern Pharmaceuticals I November 2011
Insight & Outlook: Roundtable
Will high import duties impact trade relations between India and China? The history of bilateral relations between China and India dates back to mid 1980s and it has been developing since then. Both countries are emerging economies of the world and import duty is expected to impact the bilateral trade relations. Titash Roy Choudhry
Dr Ajit Dangi President & CEO, Danssen Consulting
Ranjit Shahani Vice Chairman & Managing Director, Novartis India
Sudip Majumdar General Manager - Exports, Anglo-French Drugs
When it comes to pharmaceuticals, India imports almost 80 per cent of Active Pharmaceutical Ingredients (API) from China. We cannot compete with Chinese prices firstly due to their less stringent environment laws and also having a different political system. Financially, China is ahead than most of the countries, and strategically if India depends a lot on China then our domestic pharma market will be badly affected. Presently, the Indian bulk drugs market is suffering, and hence a more competitive environment needs to be created between India and China so that both the markets can coexist. If import duties are increased it will adversely affect the trade relations between the two emerging markets. At present, the import duty is not high but increasing the import duty is not the only solution.
Although trade between India and China has grown over the years, there is a measure of disquiet in India about its growing trade deficit with China, estimated to be around $ 14 billion. When India voiced its discontent during Commerce and Industry Minister, Anand Sharma’s visit to Beijing last year, China agreed that changes needed to be implemented. Yet, little has happened since then and the deficit has actually increased. Given its unfavourable trade scenario with China, India has sought to increase duties on products it is not dependent upon and impose non-tariff barriers where dependence is high. The skewed trade equation and resultant barriers are therefore likely to adversely impact the relationship between the two Asian giants, unless suitable measures are taken to improve the situation.
Both India and China hold more or less same positions in the global economic scenario. This in turn has further enhanced the economic relations between the two countries. These relations between the two nations are expected to improve aided by the flourishing IT and ITES sector, biotechnology industry, health sector and financial sector. The bilateral trade between the two countries is expected to reach $ 20 billion by 2008. The projected figure for 2010 is $ 30 billion. Around 90 Indian companies have set up branches in China and these companies mostly operate in the pharmaceutical sector, IT and ITES sector and automotive industry. Some of these companies are Satyam, Wipro, TCS, Ranbaxy and many more. China has already been the top trading partner of India in recent times.
Editorial take
The economic relation between the two countries is considered to be one of the most significant bilateral relations in the contemporary global economic scenario and this trend is expected to continue in the years to come. Hence, the relationship which was build for years will surely get strained if the import duties are high.
54
Modern Pharmaceuticals I November 2011
Automation Trends: Pharma manufacturing
Automation, the need of the hour
Courtesy: Cognex Inc
The Indian pharmaceutical market has grown at a phenomenal rate over the last couple of years making its presence felt in the international market. It is time to evaluate the challenges that the industry might be facing to leverage the available opportunities optimally, and automation needs a mention.
W
ith a huge domestic growth potential and an appetite to grab a larger portion of the global market, which is poised to grow at a Compounded Annual Growth Rate (CAGR) of around 6.5 per cent during 2011 to 2013, according to a research by RNCOS, Indian companies are looking at automation as the way forward. Indian pharmaceutical companies today are considering factory automation not only to reduce cost but also to meet domestic regulatory compliance, curtail counterfeiting of vital drugs and meet the stringent international standards for export consignments. The increasing competition from domestic as well as global players in countries like China and a pressure to boost operational profitability has resulted in the adoption of various types
56
of automation such as machine vision system, ID readers, robotic arms and deployment of smart IT software programs to monitor the production process. Advanced sensing technologies such as machine vision systems are today standard features in most pharmaceutical companies in developed countries. A machine vision system can match the capabilities of multiple sensors that are able to give quantitative and qualitative data about the product being manufactured. These systems provide effective and reliable feedback which allows specific robotic tools to adapt to the changing environment and track production progress. Modern factory automation employs this type of sensing technology to deliver better reliability, accuracy and speed. While vision systems
can add financial costs to an automation solution, the benefits overcome the cost of implementation in the long run providing more enhanced machine efficiency.
Implementation challenges Moving on, the pharmaceutical industry is today passing through a transition phase from a supply-driven market to a demand as well as a service-driven market, where operational efficiency will play a key role in the global dominance of Indian pharmaceutical companies. Moreover, with the recent mandate released by the Directorate General of Foreign Trade of India stipulating compulsory bar coding on export consignment of medicines, automation will now be an imperative tool even for Small and Medium Enterprises (SMEs) operating in this sector. This new law was going to come into effect on July 1st, however given the technical and financial constraints of implementing this new mechanism and pressure from local drug manufactures in India, the deadline has now been postponed to October 1st. According to this new regulation while primary-level packs will see incorporation of 2D bar codes (Data Matrix symbol) on medicines at strip, vial and bottle encoding of unique product identification code, batch number, expiry date and serial number, similar details will be displayed on the secondary and tertiary (shipper or carton) using 1D or 2D barcodes. This vital information saved in the bar code can help regulators track medical consignment to the country of origin and have access to valuable information.
Unlocking the potential Unlike barcodes, data matrix symbols can be applied directly onto the product, or to the packaging box itself. It can also be read in any orientation and can contain alphanumeric information rather than just numbers, removing the need for a ‘look up table’ of product numbers. This move has faced a lot of resistance from manufacturers because they will now be required to add various automation components to their existing machinery setup, which will drive up operational cost
Modern Pharmaceuticals I November 2011
Pharma manufacturing making Indian products less competitive as compared to products from China and Malaysia. Traditional approach of deploying turnkey serialisation solutions to meet the new regulation using integrate PC-based vision can be expensive to install, validate and maintain. That is why pharmaceutical manufacturers are increasingly opting for networked smart camera vision systems over PC-based inspection systems. Compared to PCbased systems, smart camera vision systems are generally easier to configure, validate and maintain. Because they are solid state, smart camera vision systems intrinsically provide a more stable platform than Microsoft® Windows®-based alternatives, requiring less maintenance, and fewer service pack updates and patches to install. At the machine level, which includes packaging equipment, material handling, machine controls, ID readers and vision systems, Windowsbased PCs are often unnecessarily costly to install and complex to validate when compared to smart camera vision systems. Moreover being configurable, rather than programmable, smart camera vision systems can also make it easier for manufacturers to accommodate future changes in regulations and standards. In today’s modern pharma factories the most advanced of these smart camera vision systems now offer advanced networking, communication capabilities and powerful factory integration tools. And with a standard operator interface for a common look and feel across all packaging lines and inspection points, many pharmaceutical manufacturers now consider smart camera vision systems an indispensable tool in their manufacturing process. On a broader note, although implementing the GS1 bar coding standards would put additional pressure on the manufacturing cost and Indian companies could lose out on the cost competitive edge to other developing countries industry experts believe that this measure is warranted for given the serious counterfeiting threats faced by the pharmaceutical sector especially in India.
A must have In the long run factory automation will be an important component in the entire manufacturing process. SMEs as well as large enterprises operating in India’s pharmaceutical sector will find it a necessity to implement automation at certain level in their production process. While Indian pharmaceutical manufacturers have performed well so far in adding production capacities and building economies of scale, it is time to evaluate how local corporates can further leverage automation technologies to establish their global footprint in international competitive markets. (sales.in@cognex.com)
Didier Lacroix Senior Vice President - Worldwide Sales & Marketing, Cognex Inc November 2011 I Modern Pharmaceuticals
57
Energy Management: Green engineering
Pharmaceutical manufacturers strive to save, sustain and improve quality of life. Following sustainable manufacturing processes leads to conserve and use energy efficiently, thereby leading to a reduction in its carbon footprint – the need of the day!
C
urrent strategy in the pharmaceutical industry is driven towards cost-effective protocols, which in turn helps to speed up the implementation of green chemistry and green engineering. To channelise the pollution prevention, risk management plans are followed in the industries such as source optimisation, recycling, treating the waste and pre-planned disposal. The term risk can be expressed as: Risk = f (hazard generated X exposure)
What is ‘benign by design’? Nowadays the thought is not the removal of pollutants but the precaution to reduce it on the source itself by well-designed processes, and hence, we call it as ‘benign by design’. Green chemistry is a concept of such management direction, which deals with 12 well-defined principles, including atom economy and less hazardous chemical syntheses. It can be defined as the practice of chemical science and manufacturing in a manner that is sustainable, safe, and non-
58
polluting and that involves fewer processes and energy while producing little or no undesired material. The practice of green chemistry begins with recognition that the production, processing, use and eventual disposal of chemical products may cause harm when performed incorrectly. In accomplishing its objectives, green
chemistry and green chemical engineering may modify or totally redesign chemical products and process to eliminate the use and generation of hazardous ingredients. Let us see some simple examples: Example 1: Synthesis of allyl alcohol CH2=CHCH2OH, the traditional method of alkaline hydrolysis of allyl chloride, which generates the product and hydrochloric acid as a byproduct. Alternately, we can start with propylene (CH2=CHCH3), acetic acid (CH3COOH) and oxygen (O2) by a simple two-step reaction the same product will be resulted. The by-product expected in the second step is acetic acid, which can be recycled for utilising for the first step. Hence, the unwanted waste formation can be avoided in this process. Example 2: Some researchers had showed the salt free etherification of amino acids (where H-USY is Naphtha cracking catalyst): Example 3: We had also shown the metal-free catalytic reduction of pnitrophenol to p-amino phenol by a green photocatalyst (resin supported Eosin dye) in presence of sodium borohydride under the visible light condition. By this method, the toxic p-nitorphenol can be reduced to the p-aminophenol, which is a precursor for the preparation of different pharmaceutical products, including paracetamol. The overall focus of the industry should be tuned for the ‘green quality’, and the process can be flexible to give scope for the green protocols. Such a flexibility
CONVENTIONAL: + + + NH3 CI NH3 CI NH3 MeOH/HCI (cat.) HCI (1 eq.) OOH OMe + H2O R R R O O O ZEOLITE-CATALYZED: + NH3 R O
O-
NH2
MeOH, H-USY, 1000C
OMe + H2O
R O
R= PhCH2 (aspartame intermediate); S/C = 20 (w/w), 83% yield (TON=180)
Modern Pharmaceuticals I November 2011
Green engineering
NH2
NO2 Photocatalyst
NaBH4 Visible light OH
OH
4-NP
4-AP
to make process changes can promote the green chemistry and engineering changes. Significant impacts and progress have been made in green chemistry and green engineering, including energy recovery, substitution of organic solvents and reduction, and planned utilisation of water. Solvents are considered as the major contributor to the environmental footprint from the industries. Time to time replacement of the expired patents and coping with the business economy, the industries are looking for appropriate alternates to minimise their production cost along with reduced carbon footprint pathways. Simultaneous to their core activities, the wisdom about green chemistry is growing positively. Green chemistry offer significant cost advantages and hence is part of the solution to the problem. Green Engineering is the design, commercialisation and use of processes and products that are feasible and economically viable, while minimising the risk to the human health and the
Principles of green engineering Seek wiser technologies to achieve sustainability Engineer holistically Give thought for life cycle Conserve and improve natural resources Minimise exhaustion of resources Design such that raw materials and products are safe & benign Prevent waste generation Be sensitive to local geography, aspirations and culture Engage stakeholders
60
environment by systematic reduction of generation of pollution at the source. The burden in the manufacturing cost can be controlled by efficient syntheses that avoid expensive chemicals, minimise the consumption of the energy and alternate the exotic organic solvents with the nature gifted free solvent ‘water.’
pathway than just having a perception about its cost viability.” The complexity of the pharmaceutical industry necessitates a holistic approach to greening its processes, starting with a paradigm shift from focussing only on waste management to an approach that encompasses manufacturing process efficiency, yield and economic gains for pharmaceutical companies. A barrier to greening the pharmaceutical industry is the misperception that making changes is difficult and costly. The industry has historically focussed on waste, but to incorporate green chemistry and green engineering into standard procedures, it is necessary to move away from dialogues about waste towards dialogue about efficiency.
Future directions and targets International initiations to promote the green chemistry and engineering To promote the ‘green target’, US President Bill Clinton had inaugurated the Green Chemistry Program in March 1995, which is coordinated by the Environmental Protection Agency. As part of this programme, the Green Chemistry Challenge Awards were set up, to ‘recognise and promote fundamental and innovative chemical methodologies that accomplish pollution prevention and that have broad application in industry’. Such incentives and encouragements provided more attractions to different agencies to involve in green initiatives. In 2005, a team of industries along with the American Chemical Society’s Green Chemistry Institute (GCI), established the GCI Pharmaceutical Roundtable, to encourage the amalgamation of green chemistry and green engineering in the industrial processes. There are several firms - including Pfizer, Johnson & Johnson, Astra Zeneca, GlaxoSmithKline (GSK) etc - acting as members of the roundtable. The wisdom in the industrial sectors had brought trends and models for the successful manufacturing efficiencies, and the green chemistry. Industries should recognise that “Going green is a cost-effective
Green Chemistry and Green Engineering require constant support from industry, chemists and engineers. There are many major points of actions identified and started worldwide including, The development of surfactants to be used in conjunction with supercritical CO2 as an alternative reaction solvent Conversion of glucose into chemical feed-stocks using microbial pathways Production of lactate esters from carbohydrate feed-stocks using selective membrane reactors The use of novel non-biological catalysts in the manufacture of pharmaceuticals. ‘Go green’ may be the next anticipated social movement that will set aside all the national or regional differences and will motivate the mankind towards ecofriendly ‘Green Civilisation’. (raja@chem.iitkgp.ernet.in)
Dr A Rajakumar Department of Chemistry, IIT Kharagpur
Modern Pharmaceuticals I November 2011
Policies & Regulations: FDI in Indian pharma
Evaluating the pros & cons The recent decision on Foreign Direct Investment (FDI) in pharma market has come after a lot of deliberations, discussions and persuasions. Finally, the Indian government has paid heed to the present scenario and rolled out a verdict that most believe to be balanced and effective.
Titash Roy Choudhury
T
he Indian pharmaceutical market is registering high growth rate, which is expected to continue over the years. Though majorly a generic market, several MNCs have been eyeing the Indian pharma market, primarily due to the cost factor. And so we saw several M&As or takeovers of domestic pharma companies by MNCs in the last few years and this has slowly become a concern for the domestic pharma market. With 100 per cent FDI in the Indian pharma market, there was no safeguarding of these domestic companies, which in turn would protect
62
the domestic pharma market. A high-level expert panel of the Planning Commission recommended a reduction in the present cap with the motive of retaining the predominance of Indian pharmaceutical companies, and also to maintain selfsufficiency in drug manufacturing. This panel headed by Arun Maira had presented a report, The Maira Committee Report to the Prime Minister, which stated: “It is ironic that despite India supplying quality generic drugs around the world, the country has concerns about sufficient domestic drug supply and vaccine security. With the increasing acquisition of Indian companies by transnational drug corporations, there is a pressing need to rethink our country’s drug strategy. Even when MNCs are not acquiring Indianowned drug manufacturing companies, effective control on policies and pricing may be gained through strategic alliance agreements.” And with a lot of deliberations in early October this year, the government finally passed a decision on FDI the outcome of which we have to wait and watch.
The present FDI scenario FDI is essential for bringing in sufficient competitiveness and allow for a progressive growth of any market. “Any country will not be able to manage without FDI but again too much of FDI will adversely affect the local industry. So a fine balance needs to be achieved,” believes S C Sehgal, CMD, Ozone Pharmaceuticals Ltd. After the Maira Committee Report was submitted in the latter half of September 2011, Prime Minister held a meeting with the panel on October 10, 2011 and came out with the decision that for greenfield projects 100 per cent FDI will continue to work, while for brownfield projects the FDI cap has been reduced to 49 per cent. According to the domestic market this is the first time that the government has made such a distinction between greenfield projects, which starts from the scratch and does not involve any taking over or mergers as opposed to brownfield projects, which are M&A, expansions. And according to the decision taken by the government all brownfield project, the traditional merger, acquisitions, will be allowed through the Foreign Investment Promotion Board (FIPB) approval path for a period of up to six months. After six months, the oversight will be done by the Competition Commission of India (CCI) entirely in accordance with the competition laws of the country. Green projects, presumably bringing in new technologies or new ventures from the scratch, would get automatic approval. This decision has
Modern Pharmaceuticals I November 2011
FDI in Indian pharma
A 100 per cent FDI in the pharma sector will also make a significant contribution to the overall progress of the pharmaceutical industry of India.
The decision of 49 per cent cap is a judicious one since it is neither restricting the entry of MNCs neither it is going over the board. S C Sehgal CMD, Ozone Pharmaceuticals Ltd been hailed by the local manufacturers and most of them are highly satisfied with the decision. “OPPI welcomes government’s decision to continue with 100 per cent FDI in the pharmaceutical sector making the Competition Commission of India (CCI) solely responsible for the scrutiny of M&As in the drug manufacturing field. A 100 per cent FDI in the pharma sector will continue to contribute not only to highvalue job creation, improving access to high-tech equipment and capital goods, boosting global technology co-operation in manufacturing and R&D spaces of the domestic industry, but will also make a significant contribution to the overall progress of the pharmaceutical industry of India,” says Tapan J Ray, Director, Organisation of Pharmaceutical Producers of India (OPPI).
Tapan J Ray Director, Organisation of Pharmaceutical Producers of India bolster their domestic industry, helping the nation to benefit more from FDI,” says Ray. Foreign investors look up to India for cost arbitrage and expertise in Contract Research and Manufacturing Services for improved market access. Thus, 100 per cent FDI can lead to increased domestic pharma exports. “The decision of 49 per cent cap is a judicious one since it is neither restricting the entry of MNCs neither it is going
Foreign investors look up to India for cost arbitrage and expertise in CRAMS for improved market access.
The decision’s effect on pharmaceutical market FDI in pharmaceuticals contribute significantly not only to the creation of highvalue jobs for the country, but also improve access to high-tech equipment and capital goods. “Technology cooperation with the MNCs stimulates growth in manufacturing and R&D spaces of the domestic industry. India has already suffered a 40 per cent drop in FDI between 2009 and 2010 with a 17 per cent drop in pharmaceutical FDI. Any restriction in this area will be a retrograde step in the financial reform process of India and could make overseas investment even in the R&D sector of the country less attractive, especially when appropriate safeguards are in place. Countries like China and Brazil have programs to encourage FDI and partnerships with MNCs to
64
over the board. When you do not give any challenge to the local industry that itself creates the possibilities of non-progression, but then again if you challenge them to that extent that they do not have any right to withstand the pressure then they get killed. And this is what was happening when there was 100 per cent FDI in pharma, where due to MNCs dominating the major market, the local companies were finding it very difficult to survive. When you look at the overall scenario we will see that only the big is getting bigger, while the small companies have to fight for existence, and since India has a lot of small companies a large quantum of industry was getting challenged,” says Sehgal. This
decision has also been taken by the Indian government with the motive of securing the domestic companies from MNCs since it was believed that the coming of MNCs would increase the price of the drugs. But Ray says, “Equity holding of a company has no bearing on prices or access, especially when prices are governed by the National Pharmaceutical Pricing Authority (NPPA) and competition pressure. It is because of this reason that the prices of medicines of Ranbaxy, Shantha Biotechnics and Abbott have remained stable even after acquisition.” So if pricing is irrespective of this decision, the only benefit it will bring is to safeguard the domestic market from MNCs by channelising all M&As and expansions through CCI, while on the other hand MNCs setting up companies in India has been kept at 100 per cent, which will boost the domestic market and help in creating more competition. India is also an outsourcing hub, so 100 per cent FDI for green field projects is also essential and it will boost further participation in Indian pharma market. Sehgal also believes that the process of going under the scanner of the CCI will not deter the MNCs in venturing into the progressive Indian market. “Overnight there will be no transformation, but atleast steps have been taken to create the right environment for both local and international players to thrive simultaneously in the pharma market. I think from pricing and progression and for development of Indian pharma industry along with bringing in international players, right balance will be maintained by this policy,” says Sehgal. (titash.choudhry@infomedia18.in)
Modern Pharmaceuticals I November 2011
Product Inquiry Card
5
EASY STEPS TO GET PRODUCT INFO
Product Sourcing Just Got Simpler
1 See the index page in this issue. Every product carries a number. 2 Choose products of your choice from the list. 3 Write their serial numbers (as per the index page) of your chosen product/s one-by-one in the boxes. 4 Fill in your complete contact details. 5 Send it to us at the address printed overleaf.
-1 TIPIN THE BDOUXCETS
UR O L FIL TH PR OF YO D WI ER/S EN S ND MB NU OICE A CH
-2 TIP SE ENSUILRLEIN Name:___________________________________________________Designation:_________________________________________ Company:_______________________________________________________________________________________________
F A PLE T YOU ETAILS THA THE D RED ALL REQUI
Address:_______________________________________________________________________________________________
Tel:________________________________________Mob:_______________________________Fax:_________________________ Email:__________________________________________________Web:_______________________________________________
11/2011
City:_________________________________________Pin:_______________________State:__________________________
POSTAGE WILL BE PAID BY ADDRESSEE
Business Reply Inland BR Permit No. 555 Bhavani Shankar Post Office, mumbai 400 028.
Special Project modern Pharmacuticals
InfomedIa 18 LImIted ‘A’ Wing, Ruby House, 1st floor, J K Sawant marg Dadar (W), mumbai 400 028 INDIA
NO POSTAGE STAmP NEcESSARY If POSTED IN INDIA
Strategy: Marketing of drugs
The importance of listening Marketing is the process of researching, promoting, selling and distributing a product or service. In the case of the drug industry, the sales manager not only needs to ensure greater number of prescriptions from their existing supporters but also needs to identify younger physicians who have recently started practising.
I
n any trade, marketing personnel needs to identify new areas to improve their business or sales. However, just stopping at that will not do for an ambitious entrepreneur. The search for newer indications to prescribe their old products is another way to widen the catch. This way, in addition to their captive prescriptions, many additional strips of tablets will fly off the chemist’s shelves. Once the new indication becomes accepted by key experts of the medical fraternity it is not too difficult to enlist the support of the crowd that mimics their seniors! The cycle keeps repeating till a new competitor molecule hits the market and sways its ‘superior’ tag.
between the physician and the visitors and the ‘call’ is completed.
Adding value Basic training The primary mode of training of marketing personnel, be it the junior cadre or the managerial level, is to dole out highly complex technical information in simplified terms. This familiarises the field staff with the products they are to promote. They are also trained in the field of communication and social skills. The ideal way of grooming, presenting the visual aid, the opening and closing remarks are the main points of attention while training the field staff. A small mention is made to carry feedback from doctors about the products and services. These days they go a step further and enquire whether there is ‘anything else’ that they need. As we are all aware, the undertone of these words has undergone comprehensive transformation over the years. Most medical representatives (MR) and area managers follow these instructions literally and rattle out the standard stuff and walk out of the physician’s chamber. A few minutes of ‘diplomatic banter’ ensue
68
A lot happens between the physician and the marketing people while the sales pitch is being made. Although the same MR or manager describes the same drugs to the same doctor in the same clinic, there are bits of conversation between the two that may hold deeper meaning. Busy, astute physicians make small observations or comments although they may not force their opinion strongly. Some of these remarks may hold a deeper meaning only if the pharma guy is in a frame of mind to assimilate what he is hearing. All physicians make several observations while interacting with their patients. For example, a patient may grumble about the foul smell that she gets after swallowing a pill. Another may indicate that a particular capsule is so long and sticky that it gets stuck half-way down the throat. Most doctors make a mental note of these opinions and make use of it while prescribing it to the next patient. Unpleasant experiences of a couple of patients will ensure that doctors
stop prescribing it. As long as there are effective alternatives to these drugs, many doctors may nonchalantly mention it to the concerned MR. It is up to the latter to understand the significance of the cursory remark.
Listen! ‘Most people do not listen with the intent to understand; they listen with the intent to reply.’ Listening is much different from hearing. While the former is emotional, the latter is physical. Listening involves following and understanding the sounds. It is also called ‘active listening.’ As the MR broaches a topic with the doctor check whether the doctor is listening intently or has his eyes and hands full. If the physician is busy clearing his table or picking up the phone even as his eyes are on the appointment diary, he is obviously not listening!
Modern Pharmaceuticals I November 2011
Marketing of drugs While the MR makes his sales pitch with his visual aid opened, the physician may make some comments. The remarks may pertain to the product composition, its availability or some practical observation made by his patient. Physicians sometimes discuss the taste of syrups that children like or dislike and the alert MR is expected to make quick mental notes.
Casual comments During the field staff rounds to clinics, doctors may make casual enquiries regarding adverse effects or drug interactions of some of the drugs presented. Some may enquire about the efficacy of the drug vis-à-vis another older version or he may question whether comparative Indian trials are available on the new brand presented. Few doctors are forceful in their opinions and actually insist on answers to their queries. Most of the time, such queries get reduced to a general chat with the MR or his manager. In the past decade with the mushrooming of pharmaceutical companies, specialty divisions and subdivisions, there has been a general decline in the quality of field staff. Most of these field officers hardly realise that a query has been posed to them. Since the query is not registered accurately in their minds, the same is not addressed to his superiors at sales meetings. Every casual enquiry by the physician is an opportunity to respond and reinforce the brand position by the MR. Only a keen listener can pick up the undertone in the queries of the clinician. It is these doubts which come in the way of the doctor actually writing out the next prescription. These ‘minor’ remarks can be acted upon with the MR advising his medical department to find an answer to the doctor’s comment. If the Medical Advisor reverts with the appropriate response, it will make a great impression in the doctor’s mind.
Training to listen! Listening is a natural phenomenon but unless one is actively trained in the art, much of its significance is lost. Listening may be divided into two basic types: attentive listening or reflective listening.
November 2011 I Modern Pharmaceuticals
Show that you listen 1. Pay attention Give the speaker your undivided attention Do not look at your watch or other activities Refrain from whispered side conversations 2. Show that you are alert Crossed arms can make you seem closed or negative Encourage the speaker to continue by ‘short’ verbal comments Offer facial expressions, such as a nod or a smile. 3. Provide feedback Ask related and relevant questions Reflect on what has been said by paraphrasing Seek clarification 4. Respond appropriately Avoid attacking / interrupting the speaker Respond openly and honestly, with appropriate tone of voice 5. Defer judgement Be empathic and non-judgemental Consider the communication from the speaker’s perspective Listen to the entire message before interjecting with comments
Attentive listening involves passively listening to a statement without any attempt to deny, verify or agree with the speaker. It shows interest in the matter being told while the listener is trying to understand the content as well as the intensity and tone of the speaker. Reflective listening involves showing interest in the matter being spoken but in addition, the listener attempts to think and feel what the speaker perceives as he is making his comment. Also, the reflective listener is energetically analysing the point under discussion and gets ready with a swift response. A good listener should have good control over his emotions and should be non-judgmental so as to get along with the speaker. Such an attitude will encourage the speaker to open up a bit more, thereby allowing the listener to develop better rapport with the doctor. In order to get the physician expressing his ideas freely, the listener should get along with the speaker with appropriate facial expressions. Nodding attentively and saying a few supporting words will encourage the doctor to volunteer more points.
Listening outside the clinic The field force must also be trained to look
for problems outside the doctors’ cabin, ie in the waiting room, on the road, at the chemist counter, among family and friends as well as the general neighbourhood. Patients waiting at the chemist shops make comments about the medicines or its packaging etc. Such remarks should be dutifully carried to the next sales meeting and discussed with the managers to find a solution. Overall the marketing team needs to keep listening for clues from the suffering patient as well as his doctor. Giving specific coaching to managers as well as MRs on listening to vital clues from the doctor should be a significant part of their in-house training. In a nutshell, the message is: do not just keep promoting, listen! (rajan.td@gmail.com)
Dr Rajan T D Pharma Consultant & Practising Dermatologist
69
Tips & Tricks: Refurbished pharma machinery
Things
to look
out for
while buying
Until recently, many pharma companies would never have considered buying pre-owned equipment. However, several important changes have made companies rethink this position. While the benefits of purchasing pre-owned are great, it is very different from buying new. he words ‘used equipment’ usually brings up the image of an old, broken machine with obsolete technology. But things have changed today, with increasing number of pharma companies opting for refurbished machinery. With increasing demand, necessary precautions must be
T 1
Be flexible: When buying new, one can specify the exact options they want. Pre-owned assets have pre-set options. If one starts looking for used equipment early – and build the design around what they find – they will have a much greater chance of finding equipment that meets their needs.
Tips& Tricks
2
Look for the right sources: Because of the stringent quality requirements for pharma operations, it is important to know the source of the equipment. To ensure quality, one is better off buying equipment that comes from brand name global corporations.
Tips& Tricks
3
Look in the right place: Where one shops makes a big difference on how successful – and how satisfied – one is with their experience. In order to maximise one’s chances of finding what they want, use a marketplace that offers a wide selection of equipment.
Tips& Tricks
70
taken while using/buying these machines. Matthew W Smith, Vice President – Corporate Marketing, EquipNet, Inc guides us in making the decision. If one is considering buying used equipment, here are some tips on how to ensure that the experience is a successful one.
5 T
Find expert help – honest ips and transparent: Look ricks for vendors whose staff has industry experience and expertise. Make sure they have a transparent sales process, allowing their customers to communicate directly with the seller during due diligence.
T&
6 T
Be prepared to move quickly to buy equipment that you want: When buying from an OEM, it does not matter if someone else orders the same machine; one cannot just wait for them to build a new one.
T& ips ricks
4
Understand the process: Most common ways of buying used equipment are: negotiated sales and auctions. Negotiated sales gives one more control; auctions typically offer better prices. Ensure to understand how both the approaches work, and then choose the best option.
Tips& Tricks
Matthew W Smith Vice President – Corporate Marketing, EquipNet, Inc USA
7
Be prepared to pay cash in advance: When you buy new equipment, you can often arrange for financing terms through the OEM. Used equipment, however, is a cash business: almost all purchases require cash in advance.
Tips& Tricks
8
Always inspect equipment: New equipment usually comes with a manufacturer’s warranty. Used equipment does not. As long as one is buying from reputable sources, they are unlikely to run into surprises – but why take chances?
Tips& Tricks
9
Have a plan for setting up the used equipment in your facility: Some companies do not plan well enough. They do not have staff with the equipment expertise necessary to get the equipment up and running. Avoid this by making sure of a plan for receiving the equipment.
Tips& Tricks
Modern Pharmaceuticals I November 2011
Projects New projects and expansion activities are the barometers of industrial growth. These also present business opportunities to service providers like consultants, contractors, plant & equipment suppliers and others down the value chain. This feature will keep you updated with vital information regarding new projects and capacity expansions being planned by companies in the pharma/lifesceinces industry.
Microbix Biosystems Inc Project type New facility Project news Microbix recently announced the completion of an agreement with the Chinese government for the construction of a new influenza vaccine manufacturing facility in the country. The plant is scheduled to be operational by 2013. The plant will primarily produce vaccines for the Chinese market but the company may also export them. Project location China- Central Hunan Project Cost C$ 200 Implementation stage Planning Contact details Microbic Biosystems Inc 265 Watline Avenue Mississauga, Ontario, Canada L4Z 1P3 Phone: +1-905-361-8910 | Fax: +1-905-361-8911 E-mail: microbix@microbix.com. ---------------------------------------------
National Institutes of Pharmaceutical Educational and Research Project type New facility Project news The central government has proposed six new pharmaceutical educational and research institutes in the country with the aim to set up full fledged campuses for imparting higher post graduation level education as well as to undertake research and developmental projects. Project location Gandhinagar, Hyderabad, Kolkata, Hajipur, Guwahati and Rae Bareli. Project cost ` 633.15 crore Implementation stage Planning
72
Contact details National Institute of Pharmaceutical Education and Research Sector 67, SAS Nagar - 160062 Punjab (India). Phone: +91(172)-2292000, 2214682-87 Extn.:-2174. Email: cc@niper.ac.in ---------------------------------------------
products like morphine, codeine and thebaine locally. Project location Baddi in Himachal Pradesh Project Cost $ 14-20 million Implementation stage Planning
New R&D center in Madhya Pradesh, India
Contact details Piramal Healthcare Limited Sagar Gokani/Prasad Mhatre Investor Relations Team, Piramal Healthcare Limited 247 Business Park A - Wing, 6th floor, LBS Marg, Vikroli (W) Mumbai 400083 Phone: +91 22 3095 6666 E-mail: investor.relations@piramal.com ---------------------------------------------
Project type New facility Project news The Government of Madhya Pradesh proposes to establish an integrated R&D center in the state. This center will focus on drug discovery (preclinical research) and will facilitate access to high end, comprehensive research functions at one place and ameliorate technology bottlenecks and will accelerate drug development. Project location Indore - Envisaged Pharma Cluster Project Cost $ 15.5 million Implementation stage Planning
Teva Pharmaceutical
Piramal Healthcare
Project type New facility Project news Teva Pharmaceutical would be setting up an Active Pharmaceutical Ingredient (API) plant over 100 acres of land. The project is aimed to be achieved in the next two years. Teva shall be starting the construction process post clearances by the government. Project location Gwalior, Madhya Pradesh, India. Project cost $ 1 billion, of which around $ 250 to $ 300 million will be for manufacturing facilities and the rest for the acquisition of the domestic companies. Implementation stage Planning
Project type New facility Project news Piramal Healthcare, is in the process of setting up a manufacturing unit to process raw opium for pharmaceutical use. This would help domestic pharma companies to procuring opium-based
Contact details Anant Singh Teva API India Ltd. 2G, 2H, 2I, Udyog Vihar Greater Noida 201 301 Phone: 0120-4073300 ---------------------------------------------
Contact details National Informatics Centre, Madhya Pradesh Department of Information Technology, Ministry of Communications and Information Technology, Govt. of India C-Wing, Basement, Vindhyachal Bhawan, Bhopal - 462 004. T Phone: 91-755-2551265 ---------------------------------------------
Modern Pharmaceuticals I November 2011
Event List
NATIONAL PUNE
CHENNAI
INDORE
AURANGABAD
Maharashtra, Nov 18-21, 2011, Auto Cluster Exhibition Centre
Tamil Nadu, Dec 8-11, 2011, Chennai Trade Centre
Madhya Pradesh, Jan 6-9, 2012, Poddar Plaza, Nr Gandhi Hall
Maharashtra, Feb 17-20, 2012, Garware Stadium
India’s premier industrial trade fair on products and technologies related to Machine Tools, Hydraulics & Pneumatics, Process Machinery & Equipment, Automation Instrumentation, Packaging & Auxiliaries, IT Products, Electrical & Electronics, Material Handling and Safety Equipment.
For details Infomedia 18 Ltd
Ruby House, 1st Floor, J K Sawant Marg, Dadar (W), Mumbai 400 028. • Tel: 022 3003 4651 • Fax: 022 3003 4499 • Email: engexpo@infomedia18.in
CPhI India 2011 The event will feature key decision makers in the pharma industry from 92 countries, including India, China, US, UK, France, Italy, etc. The conference will include updates on latest innovations, technologies, trends and developments in the pharmaceutical industry in India; November 30 December 2, 2011; Bombay Exhibition Centre, Mumbai For details contact: UBM India Pvt Ltd Tel: + 91 22 6612 2600 Fax: + 91 22 6612 2626-27 Email: info.india@ubm.com Website: www.ubmindia.in
9th Annual BioPharma India Convention 2011 This event aims to manage the manufacturing networks and implement effective bioprocess strategies. It also mitigates risks in upstream and downstream manufacturing operations. The event maximises the potential of disposable technologies to increase overall productivity; December 6-7, 2011; Grand Hyatt, Mumbai For details contact: Terrapinn Ltd Tel: +65 6222 8550 Fax: +65 6226 3264 Email: enquiry.sg@terrapinn.com Website: www.terrapinn.com
Pharma Technology Show This show aims at bringing together
74
world renowned companies as well as newly launched companies on one platform. This will be a meet for the top management from pharma manufacturing industry, executives from production, quality control, R&D and purchase departments, professionals from R&D institutions, pharmacists, biotechnology specialists, top officials from regulatory agencies of central & state governments, pharma consultants, and academicians from medical & pharmacy colleges; December 7-10, 2011, NSIC Exhibition Complex, New Delhi For details contact Print Packaging.Com Pvt Ltd Tel: +91 22 2781 2619/27812093/27812657 Fax: + 91-22-27812578 Email:info@indiapackagingshow.com
Lab Expo & Conferences It is a one of its kind event in the sector of lab equipment manufacturing, which will take place for two days and will include several informative sessions and workshops. These educative inclusions will be playing an important role in enriching the knowledge base of the professionals and entrepreneurs, who have been related to this profession for quite some time now. Lab Expo & Conferences - Chandigarh will be an important step forward for the makers of equipment used in professional and academic laboratories. Apart from being a platform where the industry representatives will display their products and services, this event will also make an attempt to be as much informative as possible for the first time visitors and participants; February 3-5, 2012, Parade Ground, Chandigarh For details contact: Paramount Exhibitors Tel:+ 91 172 2274801/2274802/2274803 Fax: + 91 172 2274803 Email:contact@paramountexhibitors.com www.paramountexhibitors.com
63rd Indian Pharmaceutical Congress
Pharmapack
Like the previous year, the theme of this year’s event is ‘Vision 2020: India - The Pharma Power House’. The event aims to showcase the progress made by the pharma industry in India. The unique feature of the event is the movement across the country and connecting with professionals across the country; December 16-18, 2011, Bangalore International Exhibition Centre, Bengaluru
The event aims to provide an innovative platform to showcase the latest information, technology and products to a focussed and target audience. The event promises to cater to the exporters, importers, biotechnology companies, medical device manufacturers, biopharmaceuticals, etc; February 23-25, 2012, Bombay Exhibition Centre, Mumbai
For details contact Indian Pharmaceutical Association (IPA) Tel : +91 22 2667 1072 Fax : +91 22 2667 0744 Email : ipacentre@ipapharma.org Website: www.ipapharma.org
For details contact: Intel Trade Fairs & Expositions Pvt Ltd Tel: + 91 22 2862 8126 Fax: + 91 22 2281 9008 Email: intelexpo@vsnl.net Website: www.intelexpo.com Modern Pharmaceuticals I November 2011
Event List
INTERNATIONAL BIT’s 2nd Annual World Congress of Immunodiseases and Therapy There will be discussion on the achievements of breaking research on immunodiseases, clinical immunology, drug R & D, veterinary immunology, food immunology, agricultural/aquacultural immunology and diseases control along with the emerging innovative technologies. Further, the Congress will be an important event for global immunologists and biotech entrepreneurs to discuss and exchange ideas, advanced immunotherapy, which will help to update the current advances in the fascinating area of immunology; November 18-20, 2011, Guangzhou Baiyun International Convention Center, Guangzhou, China For details contact BIT World Congress (Dalian) Inc Tel: 0086-411-84799609-827 Fax: 0086-411-84795469 Email: lee@bitlifesciences.com Website: www.bitlifesciences.com
Cell-Based Assays The event will consist of a two-day conference and a post-conference workshop, focussing on a range of topics relating to the challenges faced by those involved in using and developing cell-based assays. Thus, this event will try to resolve several concerns faced by the industry and endeavour to offer solutions to the challenges; November 21-22, 2011; Marriott Hotel Reagents Park, London, UK For details contact: SMi Conferences Tel: +44 0 870 9090 711 Fax: +44 0 870 9090 712 Email: client_services@smi-online.co.uk Website: www.smi-online.co.uk
Bio trends 2011 This meeting will take the opportunity to highlight benefits and challenges of synthetic biological techniques like using artificial gene control elements, designing synthetic circuits for host optimisation and assembling of genetic devices and modules. Such engineered cells will contribute to our understanding of the underlying design principles of living cells and will help to revolutionise our current concepts towards personalised medicine, gene therapy, tissue engineering and smart delivery systems; December 8-9, 2011, Harenberg City Center (HCC), Dortmund, Germany For details contact ChemBioTec Tel: +49 0 231 755 7391 Fax: +49 0 231 755 7382 Email: frank.eiden@chembiotec.de Website: www.chembiotec.de
9th Annual Specialty Pharmaceuticals, Oral Therapies and Injectables This conference brings together leaders from the healthcare and pharmaceutical industry to share best practices and learn how to provide quality care while also maintaining a sustainable bottom line; January 18-19, 2012, Planet Hollywood Resort & Casino; Las Vegas, Nevada, USA For details contact CBI 600 Unicorn Park Drive Woburn, MA 01801 Tel: +001- 339-298-2100 Fax: +001- 781-939-2490 Email: spex@cbinet.com
CBI’s 9th Annual Pharmaceutical Compliance Congress CBI’s Compliance Series addresses
all aspects of a corporate compliance programme to bring together Chief Compliance Officers and their teams to share best practices and evolve compliance efforts across the industry. This Series is headlined by this flagship meeting, CBI’s Annual Pharmaceutical Compliance Congress; January 24-25, 2012, The Ritz-Carlton, Washington, District of Columbia, USA. For details contact CBI 600 Unicorn Park Drive Woburn, MA 01801 Tel: +001- 339-298-2100 Fax: +001- 781-939-2490 Email: spex@cbinet.com
Biosignals 2012 The purpose of the international conference on bio-inspired systems and signal processing is to bring together researchers and practitioners f rom multiple areas of knowledge, including biology, medicine, engineering and other physical sciences, interested in studying and using models and techniques inspired from or applied to biological systems. A diversity of signal types can be found in this area, including image, audio and other biological sources of information. The analysis and use of these signals is a multidisciplinary area including signal processing, pattern recognition and computational intelligence techniques, amongst others; February 1-4, 2012, Hotel Tivoli Victoria, Vilamoura Algarve, Portugal For details contact INSTICC Tel: +351 265 520 184 Fax: +351 265 520 186 Website: www.insticc.org
The information published in this section is as per the details furnished by the respective organiser. In any case, it does not represent the views of Modern Pharmaceuticals
76
Modern Pharmaceuticals I November 2011
Event Preview: PMEC & CPhI India 2011
A congregation of the who’s who of the industry Focussing on the pharmaceutical machinery, equipment and technology, P-MEC & CPhI India is part of the largest and most comprehensive pharmaceutical events in South Asia. This year, the event will take place from November 30December 2, 2011 at the Bombay Exhibition Centre, Mumbai.
Chandreyee Bhaumik
I
ndia’s pharma machinery and equipment market is growing at 15-20 per cent per year. P-MEC aims to off er an unprecedented insight into the future of pharma equipment and machinery. Further, the event aims to highlight the latest knowledge and trends in the market. It is thus considered as the best place for one to source quality machinery and equipment at relatively competitive prices. P-MEC India is co-located with CPhI India, a sister brand of CPhI Worldwide, which is considered as the ‘must attend’ event in the international pharmaceutical industry. CPhI India aims to be a great platform for one to source high-quality ingredients and services at competitive prices. Again, this is also the place to fi nd the major suppliers of pharma ingredients, outsourcing, equipment and biosolutions in one location. Th e event aims to be a perfect meet with key decision makers in pharma industry from 92 countries, including India, China, the US, UK, France, Italy,
November 2011 I Modern Pharmaceuticals
etc. Overall, the event will provide opportunity in networking and gaining access to the world’s fastest growing pharma markets.
Glimpses from the last year Last year, P-MEC witnessed 26,436 attendees from 86 countries, including 1,433 international visitors. Further, over 71 per cent of the visitors were decision makers. The conference programme had 36 speakers and 12 modules. There were exhibitors from fields such as analytical equipment, automation & robotics, batching systems, health & safety products, instruments, laboratory products and equipment, machinery, packaging equipment & supplies, etc. Last year, reflecting the continued growth in the Active Pharmaceutical Ingredient (API), generics, fine chemicals and biopharmaceuticals industries on the Indian sub-continent, CPhI India and related pharma services events saw a 20 per cent increase in exhibitors, coupled with a 5 per cent rise in attendees. The event reflected the continued growth in region’s pharma industry. It is the largest and the most comprehensive
pharma industry event in South Asia. The previous event witnessed discussions on advanced API strategies. These included measures to drive quality and cost efficiency throughout the API industry, ways to leverage advanced manufacturing technologies and processes to ensure costeffective production of advanced APIs. Further, other seminars during the later part of the day encompassed strategies for driving export opportunities in regulated markets of the US, Europe and Japan. Presentations were given on integrated R&D, process development and methods of adopting good manufacturing practices to develop cost-effective biosimilars. The vaccine industry, which is witnessing a steady growth, was also discussed. There were talks on nanotechnology applications and commercialisation of stem cells. There were discussions on trends that showcased ways to leverage targeted drug delivery systems for anti-cancer drug development. Additionally, the leaders highlighted ways to leverage the Contract Research and Manufacturing Services (CRAMS) opportunity and suggested ways to improve the infrastructure.
Summing up… This event aims to serve as a platform for the entire pharma industry and tries to bring solutions to the several challenges faced by the industry. Similar to previous successful editions, this three-day event hopes to live up to the expectations of the industry. (chandreyee.bhaumik@infomedia18.in)
77
Event Preview: Indian Pharmaceutical Congress 2011
Showcasing India as the global pharma power house The 63rd Indian Pharmaceutical Congress (IPC) will be held in Bengaluru Exchanging knowledge and ideas from 16th-18th December 2011. The three-day event aims to serve as a With the growing knowledge and entrepreneurships, India is now platform for the exchange of new ideas among pharma professionals. recognised as one of the powerhouses
T
he 63rd edition of IPC will be hosted in Benagluru by the Indian Pharmaceutical Association, Karnataka State Branch (IPA-KSB) with the support of IPA Central. The activities during the congress are meticulously planned to ensure that science-based knowledge are ably supported to its practical application. Additionally, Pharmaceutical Expo 2011, organised by Federation of Indian Chambers of Commerce & Industry (FICCI) will run parallel to the event. Continuing the trend of ‘Vision 2020’, the theme of the event this year is ‘Vision 2020: India - The Pharma Power House.’
Strengthening the pillars IPC is an important event held every year for the pharma industry in India. The organisers consider that the four important pillars of any successful congress are scientific programme, the venue, the exhibition and the arrangement/execution of the event. The venue of the congress is the world class Bengaluru International Exhibition Centre (BIEC). Elaborating on the
78
venue, Dr B R Jagashetty, Chairman, Local Organising Committee (LOC), 63rd IPC Bengaluru, said, “The ambience is a trend setter to meet the requirements of all activities, right from networking to peer professionals debates at various strategic locations like exhibition, speaker’s corner, poster sessions and key note speeches. The congress attracts stake holders from all facets of the profession like education, regulatory and industry. Commenting on the expectations from the event, Subodh Priolkar, President, 63rd IPC, Bengaluru, says, “We have seen that the participation from the industry is receding over the last few years. This year we shall ensure that the programme is attractive to the industry. We have to see that the issues faced by the pharmaceutical industry are addressed.” He further adds, “If India has to evolve as the ‘global pharmaceutical powerhouse’, there is need to upgrade the other facets of the profession namely education and pharmacy practice. I am sure that we shall have interactive sessions on the above, resulting into document with well laid down action items to reach the desired objective.”
in the pharma field. Dr Jagashetty avers, “While we are proud to produce generic drugs at affordable prices to the world, we have the challenge to explore and discover newer therapeutic molecules. New areas for mitigation of ailments and speed of bringing them to the suffering shall provide us the opportunity to be in the cutting edge.” The scientific spread at the conference aims to address all the issues and challenges pertaining to the industry. The topics for these conferences are in line with the event’s theme and will therefore provide valuable and practical learning opportunities for all the participants. Further, the event will also have an award ceremony conducted by the IPA, Indian Hospital Pharmacists’ Association, Association of Pharmaceutical Teachers of India, Indian Pharmacy Graduates Association and All India Drugs Control Officer’s Confederation. Thus, IPC will help in disseminating scientific knowledge and therefore facilitate exchange of new ideas among the members of pharma profession.
Modern Pharmaceuticals I November 2011
Book Review
Biochemistry Biochemistry is one of the most exciting branches of scientific research. This is because it is highly interdisciplinary, enjoys a wonderful synergy with organic and inorganic chemistry, physical chemistry and physics, and of course, medicine. In the 21st century, it continues to promise us radical understanding into the working of life, and any good biochemistry book should ideally convey this excitement to the reader. This one does. It succinctly covers the basics of biochemistry, including enzyme kinetics, signal transduction, immunology, protein structure, metabolism, and biosynthesis. It also includes helpful chapters on common techniques and assays. Diagrams and illustrations help understand the material, and the text includes practice questions to solidify knowledge. Clear organisation makes the book easy to use. All of this is done in simple, straightforward language that is nonetheless pleasant to read. Stryer is the book to read if you want to learn biochemistry as a discipline, which should be viewed as an exciting excursion into human metabolism and life. Overall, this book is more than adequate for an introductory biochemistry course, and its exposition my M Berg, Authors: Jere is significantly better than most. It may not be a good text book for a zko, John L Tymoc beginner to start learning some biochemistry but for someone in the Lubert Stryer field, this text can serve as more than a simple reference. 965 Price: ` 3,
Introduction to plant biotechnology Plant biotechnology has emerged as an exciting area of plant sciences by creating unprecedented opportunities for the manipulation of biological systems. A good understanding of genetic engineering and plant tissue culture at the undergraduate level has become very critical for realising the full potential of biotechnology. This book caters to the needs of students as a text book for plant biotechnology courses and at the same time provides a practical approach to follow a technique, which is given in the form of protocols. It describes the basic aspects of gene and genome organisation in plant cells, basic tissue culture techniques and the fundamentals of cloning, gene transfer approaches and molecular markers. For good understanding of recombinant DNA technology, chapters on genetic material, organisation of DNA in the genome and basic techniques involved in recombinant DNA technology have been added. A chapter on intellectual property rights has been included to give basic information on various aspects of patenting, copyright and plant breeders. A very important point is that in most chapters emphasis is placed on application of a technique and its contribution and impact on crop improvement. This book, though primarily written for hawla C students, will be of great help to scientists. Admittedly, it is virtually S H : or th Au 0 impossible for a single author to cover all the fields. Overall, the book 35 ` : Price does a very good job.
Reviewed by: Sreya Sen, M Sc Biotechnology, St Xavier’s College, Kolkata
November 2011 I Modern Pharmaceuticals
79
Products Tablet presses
FRP storage tanks
ACG PAM PharmaTechnologies offers tablet presses (model Legacy 6100) that are flexible enough to respond to users’ varied needs. These tablet presses are robust enough to withstand large production capacities, intelligent enough to ease users’ operations, sensitive enough to respect time and, smart enough to understand economy. Some of the benefits of these tablet presses include: improved yield with control on dusting, content uniformity & contamination; online sorting of out of specification tablets at high speeds ensuring good product quality; online weight measurement & correction, ensuring consistent weight during high-speed productions; versatile single machine to address all kinds of product sizes (D, B, BB, BBS); and ability to compress all types of formulations with 10 tons compression force at 1” and 2” station.
EPP Composites offers FRP storage tanks that are manufactured by hand lay-up and/or by filament winding process for the storage of highly corrosive chemicals, acids and wastes. These storage tanks are available in capacity up to 250 kl in various shapes like square, round, rectangular vertical and horizontal with flat bottom or conical bottom. Key features include: offer resistance to chemical and weather; lightweight, easy to maintain; and feature good physical & mechanical strength. The reaction vessel is available with suitable lined agitator, gear box and electric motor. Also offered are FRP and dual laminated reaction vessels, pressure vessels and vacuum receivers for mixing, washing and filtration process.
ACG Worldwide Mumbai - Maharashtra Tel: 022-3008 9444, Fax: 022-2287 2560 Email: info@acg-world.com,Website: www.acg-pampac.com
80 80
EPP Composites Pvt Ltd Rajkot - Gujarat Tel: 02827-287059, Fax: 02827-287063 Email: marketing@epp.co.in, Website: www.atikagroup.com An ISO 9001:2008 Certified Company
Modern Pharmaceuticals I November 2011
Products Stirring hot plates Cole-Parmer India offers IKA RCT basic IKAMAG digital stirring hot plates with stronger motor for a higher speed range up to 1500 RPM and temperature control mode for faster heating of medium. The PT 1000 temperature sensors ensure precise temperature control. Maximum stirring capacity (H2O) is 20L. These feature a highly polished aluminum round top heating plate which provides efficient heat transfer than standard top plates. Hot plate features an over-temperature safety circuit adjustable from 50-310°C to protect the samples from overheating, hence suitable for unsupervised operation. The exact temperature and speed setting can be done via digital display. Hot top indicator warns to prevent burns. Bushings are according to DIN 12878 for connecting a contact thermometer enabling precise temperature control. The stirring hot plate finds applications in various industries such as process, pharmaceuticals, biotech, chemical, petrochemical, refinery, food and beverage, etc. Also offered are accessories such as temperature sensors, electronic contact thermometers, reaction vessels, stirring bars, etc. Cole-Parmer India Mumbai - Maharasthra Tel: 022-6716 2222, Fax: 022-6716 2211 Email: response@coleparmer.in, Website: www.coleparmer.in
November 2011 I Modern Pharmaceuticals
81
Products Diaphragm vacuum pumps Sri Vishnu Pumps Manufacturing Co offers diaphragm vacuum pumps and compressors that are available in capacities ranging from 10 LPM to 75 LPM. These are 100 per cent oil-free and are available in lightweight aluminium diecasting. They are practically maintenance-free. The diaphragm vacuum pumps and compressors are ideal for use in medical, pharmaceutical and miniature compressor applications. Sri Vishnu Pumps Manufacturing Co Dist Thane - Maharashtra Tel: 022-2845 8372, Fax: 022-2845 7073 Email: vishnupump@rediffmail.com, Website: www.minivacpumps.com
Push-pull meters New Concepts & Systems offers push-pull meters that are handy force measuring devices available in different ranges for measurement of push or pull force. Pushing or pulling forces are indicated by the meter on a dial of 50 mm diameter having scales ranging from 0-200 gms to 0-50 kgs for different models to suit the wide range of applications. These instruments have an additional
82 82
facility of zero adjustment and the optimum reading can be locked by means of a retaining pointer on the scale. The devices are useful in textile industries to measure or compare the stretch of the yarn Sheet or tensile strength of the yarn fibre. In pharmaceutical industries these can be used as instant tablet hardness tester. The push-pull meters also have wide applications as spring testers, wire harness joints testers, electronic keyboard and switch operating force testers and tension meters for winding and drawing applications and to find out the piercing and bursting strength of packing materials. Specially designed stand and slide assembly is available as extra attachment. The instruments are also available with specially designed handle attachment. New Concepts & Systems Mumbai - Maharashtra Tel: 022-2510 5344, Fax: 022-2511 8057, Mob: 09324787327 Email: newcons@vsnl.com, Website: www.newconsys.com
Modern Pharmaceuticals I November 2011
Products Digital vacuum indicators Ace Instruments manufactures and offers flameproof digital vacuum indicators using high accuracy vacuum transmitters in flameproof enclosures certified by CMRI, Dhanbad for high vacuum distillations carried out in the pharma and bulk drugs industry. These digital vacuum indicators come with flameproof vacuum transmitters for vacuum measuring range of 760 to 0 Torr and also in the gauge vacuum range of 0 to 760 mm Hg. Accuracy of these instruments is ±0.5 per cent FS. The flameproof vacuum indicators are direct replacement for the more cumbersome mercury Mcleod gauge and involve a more robust & reliable solidstate microcontroller design for accurate and reliable repeatability. The flameproof digital vacuum indicators are recommended for use on high vacuum distillation reactors, columns, vacuum pumps and vacuum ejector systems. These are also available with 1- or 2relay output for control or alarm indication. Optionally 4-20 mA retransmission is provided for connection onto PLCs, SCADA or data loggers. Ace Instruments Hyderabad - Andhra Pradesh Tel: 040-2307 8848, Fax: 040-2307 8848, Mob: 09394030848 Email: sales@aceinstrumentshyd.com Website: www.aceinstrumentshyd.com
November 2011 I Modern Pharmaceuticals
85
Products Tablet compression machines Shiv Pharma Engineers oers tablet compression machines (tablet press) that are used to make the tablets according to a pre-determined design. Punches and dies set into the tablet press to actually shape the tablets. These machines make tablets for a variety of industries; but their largest application is pharmaceuticals and vitamins. The machines are provided with turret made of special grade SG iron casting and interlock switches to all guard for safety of operator. Features include: paint-free compression zone, variable speed step pulley, dust extraction nozzles, anti-vibration mounting, etc. Models of the tablet compression machines available include: lab presses, single rotary tablet compression machines, double rotary tablet compression machines, and heavyduty tablet compression machines. Shiv Pharma Engineers Ahmedabad - Gujarat Tel: 079-2909 2380, Fax: 079-2909 2380 Email: sales@shivpharma.com
86 86
Modern Pharmaceuticals I November 2011
Products Dispensing machines Jacsons Engineers offers dispensing machines that are mostly used for dispensing, counting of empty pouch, filled flat pouch, paper, paper bags, carton poly bags, etc. The machines’ speed ranges fron 0 to 400 per/min. Range of product is minimum 50 mm x 70 mm and maximum 210 mm x 350 mm. Thickness of the dispensing units is 70 GSM paper to 10 mm thickness size (but should be flat). Optional if required: counter/ printer (as extra provision). Jacsons Engineers Ahmedabad - Gujarat Tel: 079-2584 1814, Fax: 079-2584 1408, Mob: 09426518809 Email: info@jacsonsengrs.com , Website: www.jacsonsengrs.com
Precision melt supermix Bio-Rad Laboratories offers the new precision melt supermix that delivers robust high resolution melt (HRM) performance for sensitive and accurate detection of single nucleotide polymorphisms (SNP) and CpG methylation for epigenetic studies. The PCR reagent is compatible with all HRM-capable thermal cyclers. Traditional genotyping methods, such as denaturing high-pressure liquid chromatography (dHPLC) and single-strand conformation polymorphism (SSCP), involve lengthy protocols and require
November 2011 I Modern Pharmaceuticals
multiple days for completion. Probe-based genotyping can be expensive, especially for large numbers of SNPs. HRM is a simple, rapid, and inexpensive alternative for studying genetic variation. The precision melt supermix was optimised specifically for accurate, robust, and reproducible HRM discrimination. By employing the saturating EvaGreen dye, which is required for detection of class III/IV SNPs, the supermix discriminates all four SNP classes across a broad range of amplicons. This allows for any genomic region to be studied, regardless of amplicon length and GC content. The supermix is also fully compatible with bisulfiteconverted DNA and allows for accurate detection of CpG methylation status. Furthermore, the precision melt supermix’s room temperature stability allows researchers to screen thousands of samples using Bio-Rad’s CFX96 Touch or CFX384 Touch real-time PCR systems with the CFX automation system for high-throughput HRM analysis. Bio-Rad Laboratories California - USA Tel: +1-800-2246723, Fax: +1-510-7416373 Email: diagcs@bio-rad.com, Website: www.bio-rad.com
87
Products Liquid-ring vacuum pumps
Pharma inspection machines
world. Some of the current product developments include diamond packet folding machines, quality inspection systems, pharma code readers, etc. Also offered are automatic paper folding machines, pharma inspection systems and a range of customised solutions as per pharma industry requirements. Pharma inspection solutions include: pharmacode readers, leaflets and cartons. These have been specially designed for online checking of pharma codes printed on tubes, cartons, leaflets, labels, etc. Features include: standard pharma codes; mini pharma codes; inverse printed pharma codes; can support simultaneously up to 2 bar codes readers; speed up to 300 readings per minute; 64-product memory; program selection through product name or code; simple operation by means of a touchscreen; and separate password is given to one supervisor & one operator. Applications are in pharmaceutical and pesticide literature, sales promotion material, booklets, diaries, etc.
Pratham Technologies manufactures and offers paper folding, shrink pack and pharma inspection machines and their accessories. These machines are also tested for CE marking, and thus fulfill one of the major statutory requirements of European Union. The machines are benchmarked with the latest machines in the
Pratham Technologies Pvt Ltd Pune - Maharashtra Tel: 09822047399, Email: marketing@prathamtech.com, Website: www.prathamtech.com
Blowtech offers liquidring vacuum pumps and compressors. These have airflow from 51 m³/hr to 440 m³/hr. They have maximum vacuum of 50 Torr (abs). The liquid-ring vacuum pumps and compressors are available in CI, GBZ, and SS304/316 materials of construction. These are ideally suited for chemical, pharmaceutical, paper and textile industries. Other range of products include oil-sealed high vacuum pumps, and industrial vacuum cleaners & dust collectors. Blowtech Dist Thane - Maharashtra Tel: 022-2845 8372, Fax: 022-2845 7073 Email: blowtech@hotmail.com, aWebsite: www.vacuumcleanerindia.com
88 88
Modern Pharmaceuticals I November 2011
Products PID controllers Omron Automation offers PID controllers in different sizes. Model E5CZ is a 2 PID control in 48 mm x 48 mm size with shortest depth of just 68 mm. It comes with relay/SSR and current output option.These controllers are ideal temperature controlling devices with sampling time of 250 m sec. The IP66 protection makes them ideal choice for plastics, packaging and pharmaceuticals industries. Model E5CZ/EZ/AZ PID controllers are available with all kind of TC/RTD and analog input to make it universal for many applications. These come with user-friendly key operations and PID/ on-off selectable mode, which makes them much more simple and acceptable. The RS485 optional feature provides facility to view and control the parameters from remote location. Omron Automation Pvt Ltd Bengaluru - Karnataka Tel: 080-4072 6400, Fax: 080-4146 6403, Mob: 09980943045 Email: in_enquiry@ap.omron.com, Website: www.omron-ap.co.in
The information published in this section is as per the details furnished by the respective manufacturer/ distributor. In any case, it does not represent the views of
Modern Pharmaceuticals
November 2011 I Modern Pharmaceuticals
89
List of Products Sl No 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85
Product
Pg No
AC motors ...........................................31 Access controls ......................................... 81 Acoustic enclosures .................................. 63 Agitators ................................................... 29 Air die grinders ........................................ 73 Air filters ............................................ 49, 51 Air shower controllers.............................. 81 Air treatments .......................................... 12 Alpha presses............................................ 61 Analytical instrumentation ...................... 55 Analytical instruments ............................. 92 Autoclave gaskets ..................................... 15 Autoclaves .......................................... 17, 45 Axial flow fans ......................................... 81 Bag filters ............................................85 Ball check valves ................................ 10, 82 Ball valves .....................................35, 73, 82 Batch dispersers ....................................... 29 Bellows & dip pipes ................................ 35 Biological safety cabinets ................... 49, 51 Blow/fill/seal machines ........................ 8, 19 Booklet & leaflet labels ........................... 23 Braided hoses ........................................... 15 Brake motors ............................................ 31 Bushes....................................................... 82 Butterfly valves ................................... 35, 82 Cables..................................................15 Calorimeters ............................................. 29 Capsule filling machines.................... 17, 45 Carbon filters ........................................... 85 Cartoners ............................................ 17, 45 Cartridge filters ........................................ 85 Centrifugal air blowers ............................ 81 Check valves............................................. 35 Chromatography ...................................... 92 Cleanroom doors ............................... 49, 51 Coating machines .................................... 61 Cod anaylsers ........................................... 57 Coding.................................................COC Colloid mills............................................. 61 Columns & chemistries........................... 55 Columns ................................................... 92 Communicating mills .............................. 61 Coolant pipes ........................................... 73 Cooling towers ......................................... 12 Cords ........................................................ 15 Corona treater sleeves .............................. 15 Counters & power supplies .................. FIC DC motors ..........................................31 De-dusting & de-burring........................ 61 Dehumidifiers .......................................... 16 Diaphragm vacuum pumps ..................... 82 Diaphragm valves..................................... 82 Digital temperature controllers ............... 87 Digital vacuum indicators........................ 85 Dispensing booths ............................. 49, 51 Dispensing machines ............................... 87 Dispersers ................................................. 29 Door interlock systems ............................ 81 Double rotary tableting machines ........... 61 Drives ....................................................... 87 Dry vacuum pumps ................................. 85 Dry vane pumps ...................................... 63 Drying ovens ............................................ 61 Dual channel with modbus ..................... 87 Duel fuel burners ..................................... 81 Duo labels ................................................ 23 Dust extractors ......................................... 61 Dynamic controllers................................. 87 Electricals ............................................81 Elemental analysis.................................... 92 Empower .................................................. 55 Encoders ................................................ FIC EngineeringExpo exhibition ................... 40 Equal tee .................................................. 10 Exhibitions ............................................... 40 Expansion bellows ................................... 10 Fan filter units ............................... 49, 51 FBD gaskets............................................. 15 FEP lined ball/plug valves....................... 10 FEP/PFA/PVDF materials..................... 82 Filling equipment ..................................... 75 Filling machines ....................................... 89 Filter housings & assemblies ................... 85 Filter press ................................................ 86
Sl No 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168
Product
Pg No
Fire alarms ................................................ 81 Fittings................................................ 10, 82 Flag labels................................................. 23 Flameproof motors .................................. 31 Flange mounting motors ......................... 31 Fluid bed dryers ....................................... 81 Fluid bed processors ................................ 61 Fluid bed systems .................................... 61 Fluoropolymer lined valves...................... 10 Foot valves ................................................ 73 FRP storage tanks.................................... 80 Gas detectors .......................................57 Gaskets ............................................... 15, 82 Gear pumps.............................................. 71 Geared boxes ............................................ 67 Geared motors ......................................... 67 Giga presses.............................................. 61 Hand valves .........................................73 Hanger labels ........................................... 23 Heart valve frames ................................... 53 Heating baths........................................... 29 Heating range .......................................... 85 HEPA filter terminal housings ......... 49, 51 High efficiency mills................................ 89 High pressure homogenisers ................... 29 Horizontal form-fill-seal-packaging machines ................................................ 59 Hot plates................................................. 29 Hot water generators ............................... 81 HPLCs ............................................... 55, 92 Hydraulic hoses........................................ 73 Hydraulic solenoid valves ........................ 73 Indirect air heaters ...............................81 Industrial control & sensing devices .... FIC Industrial coolers ...................................... 12 Industrial ovens ........................................ 81 Industrial pumps ...................................... 88 Inflatable gaskets ...................................... 15 Informatics ............................................... 55 Injectable manufacturing lines .......... 49, 51 Inline dispersers ....................................... 29 Inspection machines ................................ 43 Inspection systems ................................... 21 Inverter/variable frequency drives ........ FIC ISO cylinders ........................................... 73 Kamlok & drylok couplings.................88 Kneading machines.................................. 29 Lab equipment- analytical range ..........85 Labelling equipment ................................ 75 Labelling machines .......................COC, 43 Laboratory mills....................................... 89 Laboratory reactors .................................. 29 Laboratory software ................................. 29 Laminar air flow workstations .......... 49, 51 Level controllers.................................... FIC Lined ball valves....................................... 10 Lined valves & pipe fittings .................... 35 Lined valves.............................................. 10 Liquid filling machines............................ 43 Liquid injectable equipment.................... 75 Liquid manufacturing plants ................... 75 Liquid sterile filling machines ........... 17, 45 Liquid-ring vacuum pumps..................... 88 Loading arms ........................................... 88 Machines & plants ..............................86 Magnetic stirrers ...................................... 29 Marking machines ..............................COC Mass mixer granulators ........................... 61 Mass spectroscopy.................................... 92 Measuring & monitoring relays........... FIC Mega presses ............................................ 61 Mills.......................................................... 29 Mini roll compactors ............................... 61 Minin cm mills ........................................ 61 Molecular spectroscopy............................ 92 Monoblock high vacuum pump.............. 85 Motion controls .................................... FIC Motors ...................................................... 31 Nano mills ...........................................89 Non-return valves .................................... 35 Nozzles ..................................................... 88 Oil seal high vacuum pumps ................85 Oil seals .................................................... 15 Ointment/lotion/cream manufacturing plants ...................................................... 75
Sl No 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248
Product
Pg No
Online b2b marketplace .................... 33, 90 Online weighing systems......................... 43 Optical range............................................ 85 O-rings ..................................................... 15 Overhead stirrers...................................... 29 Pass box interlock systems ...................81 Pass boxes ........................................... 49, 51 PBEGL geared motors ........................... 31 Pesticide spray hoses ................................ 73 PFA lined ball/plug valves....................... 10 PFA lined fittings .................................... 10 PFA lined products.................................. 10 Pharma inspection machines................... 88 Pharma manufacturing solutions .........BIC Pharma packaging solutions.................BIC Photoelectric sensors............................. FIC PID controllers ........................................ 87 PID controllers ........................................ 89 Pilot plants ............................................... 29 Pilot presses .............................................. 61 Pipes ......................................................... 82 Piping systems...................................... 7, 10 Platinum cured lilicons tubings............... 85 PLCs ........................................................ 87 Pleated filters............................................ 85 Plug valves ................................................ 82 Polypropylene filter plates........................ 86 Polypropylene recess plates ...................... 86 Powder & granule packing equipment ... 75 Powder filling machines .......................... 43 Powder granulation equipment ............... 75 Pp-recess chamber-type filter presses ..... 86 Pp-recess chamber-type fully automatic filter presses............................................ 86 Precision melt supermix........................... 87 Pre-engineered & pre-fabricated modular panel .................................. 49, 51 Pressure gauges......................................... 73 Profile controllers ..................................... 87 Profiles ...................................................... 15 Programmable logic controllers............ FIC Programmable terminals....................... FIC Proximity sensors .................................. FIC PTFE lined ball check valves ................. 10 PTFE lined fittings ................................. 10 PTFE lined pipes .................................... 10 PTFE lined products............................... 10 PTFE lined spool pipes .......................... 10 PTFE lined valves & pipe fittings.......... 35 PTFE Teflon braided hoses .................... 73 PTFE ....................................................... 82 PU tubes................................................... 73 Pumps...........................................63, 71, 85 Punches & dies ........................................ 61 Pure steam generators........................ 17, 45 Push-pull meters ...................................... 82 Quick change terminal hoses ......... 49, 51 R&D solutions ................................ BIC Rapid endotoxin detection systems......... 89 Receptacles ............................................... 88 Regulators................................................. 73 Return air risers.................................. 49, 51 RFID ..................................................... FIC Rock drill hoses ....................................... 73 Rods.......................................................... 82 Roll compactors ....................................... 61 Roots blowers ........................................... 63 Roots vacuum pumps .............................. 85 Rotary evaporators ................................... 29 Rotary gear pumps................................... 71 Rotary pumps........................................... 85 Rupid mixers ............................................ 61 Safe change housing ...................... 49, 51 Safety light curtains .............................. FIC Sampling booth.................................. 49, 51 Sampling valves........................................ 35 Sealing equipment ................................... 75 Sealing machines...................................... 43 Sections .................................................... 15 SEZ developers ....................................FGF Shakers ..................................................... 29 Sheets ................................................. 15, 82
Sl No
Product
Pg No
249 Sight flow meters ..................................... 88 250 Silicone rubber sleeves ............................. 15 251 Silicone transparent platinum cured tubings.................................................... 15 252 Single rotary tableting machines ............. 61 253 Single stage monoblock vacuum pumps..................................................... 85 254 Single-stage vacuum pumps .................... 85 255 Slipring crane-duty motors ..................... 31 256 Solenoid valves ......................................... 73 257 Solid-liquid mixers................................... 29 258 Sponges .................................................... 15 259 Spool pipes ............................................... 10 260 Spun filters ............................................... 85 261 Squares ..................................................... 15 262 SS hose clip .............................................. 73 263 Stainless steel filters ................................. 85 264 Steam boilers ............................................ 81 265 Steel wire & duct hose ............................ 73 266 Sterilising/depyrogenating tunnel ...... 49,51 267 Stirring hot plates .................................... 81 268 Strainers.................................................... 35 269 Strips......................................................... 15 270 Swing check valves .................................. 82 271 Switching relays .................................... FIC 272 Swivels ...................................................... 88 273 Syringes for liquid injetable filling machines ................................................ 43 274 Syrup manufacturing plant...................... 75 275 Tablet compression machines ..............86 276 Tablet presses ........................................... 80 277 Tablet/capsule packing equipment .......... 75 278 TC gaskets ............................................... 15 279 Teflon-lined ball valves ............................ 35 280 Teflon-lined butterfly valves .................... 35 281 Teflon-lined check valves ........................ 35 282 Teflon-lined sampling valves ................... 35 283 Teflon-lined strainers ............................... 35 284 Teflon-lined valves & pipe fittings ......... 35 285 Tefzel HHS isotactic PP materials ........... 7 286 Temperature controllers .................. FIC, 87 287 Thermic fluid heaters ............................... 81 288 Thermoplastic valves .................................. 7 289 Thermostats & vacuum dryers/mixers .... 29 290 Three parameter displays ......................... 81 291 Timers ................................................... FIC 292 Transparent tubings ................................. 15 293 Tray dryers................................................ 81 294 Tubes ........................................................ 82 295 Twin-screw co-rotating extruders ........... 53 296 Twin-screw elements ............................... 53 297 Twin-screw extruders............................... 53 298 Two-stage vacuum pumps ....................... 85 299 UHPLCs .............................................92 300 Universal controller .................................. 87 301 UPLCs ..................................................... 55 302 Vacuum booster pumps ........................63 303 Vacuum pads ............................................ 73 304 Vacuum pumps ........................................ 85 305 Vacuum range .......................................... 85 306 Vacuum systems ....................................... 63 307 Valves .................................................. 10, 82 308 Vision sensors........................................ FIC 309 Washing/cleaning machines ................43 310 Water for injection generation stills........ 17 311 Water for injection generation stills........ 45 312 Zero liquid discharge effluent treatment .........................................BC
Looking for a specific product? We will find the product for you. Just type MPH (space) Name of the Product and send it to 51818 eg, MPH (space) Bioreactor and send it to 51818.
BC-Back cover, BIC-Back inside cover, COC-Cover on cover, FGC-Front gate fold, FIC-Front inside cover
90
Modern Pharmaceuticals I November 2011
List of Advertisers Advertiser’s Name & Contact Details ACG Worldwide T: +91-22-26780127 E: shabir.badami@acg-worldwide.com W: www.acg-worldwide.com Aerotherm Systems Pvt Ltd T: +91-79-25890158 E: contact@aerothermsystems.com W: www.aerothermsystems.com ANI Engineers T: +91-2752-241479 E: anivarya@sancharnet.in W: www.anivaryapumps.com Arctic India Sales T: +91-11-23906777 E: bryairmarketing@pahwa.com W: www.bryair.com Bosch Limited T: +91-80-41768218 E: narendra.S@in.bosch.com W: www.boschindia.com/pa Chamunda Pharma Machinery Pvt Ltd T: +91-79-25842712 E: shahil@cm1981.com W: www.cm1981.com Charles River T: +91-80-25588175 E: india.customercare@crl.com W: www.criver.com Chitra Precious Mechtech Pvt Ltd T: +91-79-25840315 E: contact@chitramechtech.com W: www.chitramechtech.com Dip-Flon Engineering Co T: +91-79-25624003 E: dipflon@satyam.net.in W: www.dipflon.com Eltech Services Pvt Ltd
Pg No BIC
81
71
16
E: process@ika.in W: www.ika.in IndiaMART InterMESH Limited E: pr@indiamart.com W: www.indiamart.com J B Sez Pvt Ltd
17,45
61
89
75
29
33,90
FGF
E: aparadkar@jbsez.com W: www.jbsez.com Joyam Engineers & Consultants Pvt Ltd 85 T: +91-79-26569533 E: joyam@joyamvactech.com W: www.joyamvactech.com Markem-Image India Private Limited COC T: +91-120- 4099500 E: salesindia@markem-imaje.com W: www.markem-imaje.co.in Mifa Systems 87 T: +91-79-26870825 E: sales@mifasystems.com W: www.mifasystems.com Milltech Engineering Pvt Ltd 89
T: +91-22-41610099 10
81
E: sales@milltechengg.com W: www.milltechengg.com N K P Pharma Pvt Ltd T: +91-79-25890834 E: domestic@nkppharma.com W: www.nkppharma.com Netzsch Technologies India Pvt Ltd
43
86
T: +91-44-42965121 40
63
E: anton.benjamin@nti.netzsch.com W: www.netzsch-grinding.com/pharma Nichrome India Ltd T: +91-20-66011001 E: marketing@nichrome.com W: www.nichrome.com Omron Automation Pvt Ltd
59
49,51
88
Pg No
Salesworth Synergies Pvt Ltd(Seidenadger)
21
E: mail@salesworth.com W: www.seidenader.de Samson Extrusion Ind Pvt Ltd T: +91-22-23422238 E: samson7@vsnl.com W: www.samson-grp.com Shah Brothers T: +91-22-43560400 E: coupling@shahbros.com W: www.shahbros.com SSP Pvt Limited
73
85
BC
T: +91-129-4183700 E: info@sspindia.com W: www.sspindia.com Steer Engineering Pvt Ltd
53
T: +91-80-23723309 E: info@steerworld.com W: www.steerworld.com Supremo Line & Control T: +91-79-22205282 E: supremoproduct@gmail.com W: www.supremoproduct.com Suresh Enterprises
82
15
T: +91-2762-224814 E: info@sevitsil.com W: www.sevitsil.com The Indian Electric Co T: +91-20-24474303 E: icemktg@indianelectric.com W: www.indianelectric.com Thermo Fisher Scientific Sid Division
31
92
T: +91-22-67429494 E: pradeep.kumar@thermofisher.com W: www.thermofisher.com Uniphos Envirotronic Pvt Ltd
57
T: +91-22-6123500 E: singhrv@unipos.com W: www.uniphos-she.com UNP Polyvalves India Pvt Ltd T: +91-265-2649248 E: mktg@polyvalve.com W: www.polyvalve.com Waters (India) Private Limited
7
55
T: +91-80-28371900 FIC
T: +91-80-40726400 E: in_enquiry@ap.omron.com W: www.omron-ap.com Pierlite India Pvt Ltd T: +91-79-22782623 E: pradeep@pierlite.co.in W: www.pierlite.co.in Premium Transmission Ltd
Advertiser’s Name & Contact Details
T: +91-80-25274495
T: +91-22-66210000
80
E: waters_india@waters.com W: www.waters.com Weiler Engineering Inc T: +847-531-6733 E: creed@weilerengineering.com W: www.weilerengineering.com
8
67
T: +91-20-66314100 12
T: +91-422-3267800 E: sales@gemindia.com W: www.gemindia.com Heattrans Equipments Pvt Ltd T: +91-79-25840105 E: info@heattrans.com W: www.heattrans.com
35
T: +1800-200-4444
T: +91-22-61592900 E: mails@fabtecheng.com W: www.fabtecheng.ae Fluid Energy Controls Inc T: +91-44-42083536 E: sales@fecindia.com W: www.fecindia.com Gem Equipments Ltd
Hi-Tech Applicator T: +91-79-25833040 E: hitech@ptfeindia.com W: www.ptfeindia.com IKA India Private Limited
Pg No
T: +91-80-26253900
T: +91-40-27759895 E: sales@eltechservices.com W: www.eltechservices.com Engineering Expo T: +91-09819552270 E: engexpo@infomedia18.in W: www.engg-expo.com Everest Transmission T: +91-11-45457777 E: info@everestblowers.com W: www.everestblowers.com Fabtech Technologies Intl Pvt Ltd
Advertiser’s Name & Contact Details
86
W: www.premiumtransmission.com Reynders Label Printing India Pvt Ltd T: +91-149-3305400 E: india@reynders.com W: www.reynders.com Salesworth Synergies Pvt Ltd(Rommelag)
T: +91-80-25274495 E: mail@salesworth.com W: www.rommelag.com
23
Looking for a specific product?
19
We will find the product for you. Just type MPH (space) Name of the Product and send it to 51818 eg, MPH (space) Bioreactor and send it to 51818.
BC-Back cover, BIC-Back inside cover, COC-Cover on cover, FGC-Front gate fold, FIC-Front inside cover
Our consistent advertisers
COMPLETE ENGINEERING UNDER ONE ROOF @ www.engg-expo.com
November 2011 I Modern Pharmaceuticals
91
Modern Pharmaceuticals
RNI No: MAHENG / 2008 / 27125 Postal Regd No: G / NMD / 122 / 2011 - 13 Posted at P.C Stg. OfďŹ ce, GPO, Mumbai 400 001 On 19th & 20th Of Every Month Date Of Publication: 16th Of Every Month
November 2011
94